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Abstract: There have been significant advances in the understanding 
of the biology and treatment of non–small-cell lung cancer (NSCLC) 
during the past few years. A number of molecularly targeted agents 
are in the clinic or in development for patients with advanced 
NSCLC. We are beginning to understand the mechanisms of acquired 
resistance after exposure to tyrosine kinase inhibitors in patients with 
oncogene addicted NSCLC. The advent of next-generation sequenc-
ing has enabled to study comprehensively genomic alterations in 
lung cancer. Finally, early results from immune checkpoint inhibitors 
are very encouraging. This review summarizes recent advances in 
the area of cancer genomics, targeted therapies, and immunotherapy.
Key Words: Non–small-cell lung cancer, Targeted therapies, 
Immunotherapy.
(J Thorac Oncol. 2015;10: S1–S63)
MOLECULAR GENETICS OF HUMAN  
LUNG CANCER
Lung cancer has traditionally been classified by histologic 
subtype and immunohistochemical characteristics. However, this 
classification has been complicated by the recognition that sev-
eral clinically actionable somatic genetic alterations can be iden-
tified in the distinct histologic subtype of lung cancer and that 
some of these alterations can be found in more than one histol-
ogy. Through comprehensive genomic analysis, it is known that 
all lung cancers carry high rates of somatic mutation, high levels 
of inter- and intra-chromosomal rearrangement, and copy-num-
ber alterations as compared with other tumor types.1 Exploitation 
of these genomic aberrations has become an attractive and effica-
cious treatment strategy and has underscored the need for multi-
plexed genetic testing as part of the routine care of patients with 
lung cancer. To stratify patients into clinically relevant subgroups, 
the combination of histomorphological, immunohistochemical, 
and genetic analysis is now used routinely for patients with newly 
diagnosed lung cancer and is the standard of care in newly diag-
nosed adenocarcinoma in which epidermal growth factor recep-
tor (EGFR) mutation and anaplastic lymphoma kinase (ALK) 
rearrangement testing have been incorporated into standard treat-
ment algorithms. In addition, many institutions are now routinely 
testing for alterations such as ROS proto-oncogene 1 (ROS 1), 
RET, B-Raf proto-oncogene (BRAF), and v-erb-b2 avian eryth-
roblastic leukemia viral oncogene homolog 2 (HER2) which have 
shown initial promise in tailored cancer treatment.
Lung Adenocarcinoma
Lung adenocarcinoma is one of the best genetically 
characterized human epithelial malignancies and recent dis-
coveries of targetable driver mutations have highlighted the 
impressive cadre of molecular alterations present in this dis-
ease. The identification of oncogenic activation of particular 
tyrosine kinases (TK) in some patients with advanced non–
small-cell lung cancer (NSCLC) most notably mutations 
in EGFR2–4 or rearrangements of the ALK gene5 has led to 
a paradigm shift and the development of specific molecu-
lar treatments for patients. These clinical successes have 
revolutionized the field and stimulated the investigation into 
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additional, potential targetable, generation aberrations across 
all lung cancer histologies (Fig. 1 and Table 1).
For patients with lung adenocarcinoma, the impact of 
genetic testing has led to changes in the standard diagnos-
tic algorithms with recommendations from the International 
Association for the Study of Lung Cancer and National 
Comprehensive Cancer Network that newly diagnosed 
patients with advanced disease be tested for EGFR mutation 
and ALK fusion testing. In addition, many institutions are now 
routinely testing for alterations in genes such as ROS, RET, 
MET proto-oncogene (MET), BRAF, and HER2 which have 
shown initial promise in tailored cancer treatment.
The need to perform detailed molecular testing of lung 
cancers began with the correlation of EGFR mutations and sensi-
tivity to gefitinib and erlotinib in lung adenocarcinoma, typically 
in patients with modest tobacco exposure EGFR TK inhibitors 
(TKIs) are now the established first-line therapy in patients with 
NSCLC known to have activating mutations in EGFR.6,7 The 
majority of these tumors initially respond to EGFR TKIs, but 
subsequently develop resistance to therapy, with a median time 
to progression of 9 months.8 Recent work has demonstrated the 
value of additional molecular testing at the time of acquired resis-
tance in EGFR-TKI–responsive patients, as nearly half of patients 
with disease progression will carry a secondary EGFR mutation, 
such as T790M, which can now be successfully targeted with 
third-generation EGFR TKIs such as AZD9291 and CO-1686.8,9 
Additional mechanisms of resistance to EGFR inhibitors have 
been defined in rebiopsy cohorts, many of which are associated 
with a potential for response to other targeted agents or with 
response to other chemotherapies (small cell transformation).8
Receptor TK (RTK) gene rearrangements, such as ALK, 
ROS, and RET, are identified in 1% to 8% of lung adenocarci-
nomas.10 patients whose tumors harbor ALK fusion and ROS1 
rearrangements demonstrate a response to crizotinib and other 
TKIs.11,2 However, similar to their EGFR counterparts, these 
patients ultimately recur. This has led to molecular character-
ization of mechanisms of acquired resistance and the clinical 
use of ALK and ROS inhibitors with expanded mechanisms of 
action such as LDK378.
Interestingly, some of the most frequent genomic altera-
tions in adenocarcinoma, such as mutations in tumor protein 
p53 (Tp53), KRAS, and serine/threonine kinase 11 (STK11), 
have proven difficult to target and therapeutically exploit.13,14 
The mitogen activation pathway (MApK) is often implicated 
in the development of lung adenocarcinoma; however, little 
success has been garnered therapeutically. The most com-
mon mechanism for MApK activation is through substitu-
tions mutations in 12th, 13th, and 61st amino acids of KRAS. 
Activating KRAS mutations are observed in approximately 
20% to 25% of lung adenocarcinomas in the United States 
and are generally associated with a history of smoking. The 
presence of a KRAS mutation appears to have at most a lim-
ited effect on overall survival (OS) in patients with early-stage 
NSCLC although some data have suggested that it was associ-
ated with inferior prognosis. Efforts to identify specific inhibi-
tors for KRAS-mutated lung cancer have proven challenging 
with the current focus of targeted therapeutics for patients 
with KRAS-mutated lung cancer is against downstream effec-
tors of activated KRAS such as mitogen-activated protein 
kinase kinase (MEK) 1/MEK2, phosphatidylinositol 3-kinase 
(pI3K), and v-akt murine thymoma viral oncogene homolog 
(AKT). Recent phase II data examining combination use of 
selumetenib, an inhibitor of MEK1/MEK2, and docetaxel 
has been shown to have promising activity in KRAS-mutant 
patient population.15 Additional work on downstream effectors 
in the KRAS-mutant pathway is crucial, and currently, several 
clinical trials using the inhibition of phosphatidylinositol-
4,5-bisphosphate 3-kinase, catalytic subunit alpha (pI3KCA), 
MEK, and phosphatase and tensin homology deleted on chro-
mosome 10 (pTEN) are in progress.
Squamous Cell Lung Cancer
Genotyping alone has improved survival in patients who 
harbor a targetable mutation such as EGFR mutation and echi-
noderm microtubule associated protein like 4 (EML4-ALK) 
fusions. However, there has been limited advancement in tar-
geted approaches in squamous cell carcinoma until recently. 
Recent genomic profiling in squamous cell carcinoma has 
highlighted a number of new molecular targets including 
the fibroblast growth factor receptor (FGFR) family kinases. 
FGFRs are cell surface TK receptors that mediates cell sur-
vival and proliferation. Gene amplification of FGFR1 has 
been detected in 7% to 25% of squamous tumors, and exten-
sive profiling has identified low-frequency activating muta-
tions and copy-number alterations in all the FGFRs.16–18 Small 
molecule inhibitors of FGFR1 are in clinical development, 
and a case report of a NSCLC patient with tumor regression 
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been presented.19 In addition, a number of different mutations 
have been identified in FGFR2 and FGFR3, including a recur-
rent fusion of FGFR3 and transforming, acidic coiled-coil 
containing protein 3 (TACC3), which provides much needed 
insight into the oncogenic pathways operating in SCC and 
makes a strong case for applying FGFR inhibitors in this dis-
ease.20–22 Targetable alterations in lung squamous cell carci-
nomas also include members of the pI3K pathway, discoidin 
domain receptor tyrosine kinase 2 (DDR2), and potentially 
the nuclear factor, erythroid 2-like 2 (NFE2L2)/kelch-like 
ECH-associated protein 1 Keap1)/cullin 3 (CUL3) antioxidant 
response pathway. In contrast to lung adenocarcinomas, there 
does not seem to be a substantial cohort of nonsmokers with 




With the development of targeted agents, the treatment 
paradigm of NSCLC continues to evolve; however, the dis-
covery of a clinically actionable mutation in small-cell lung 
cancer (SCLC) remains elusive. SCLC remains an exception-
ally aggressive malignancy with limited treatment options in 
the relapsed/refractory setting. SCLC has a high mutation rate, 
likely secondary to tobacco carcinogen exposure in this patient 
population. This high rate of mutation makes the identification 
of pathologically relevant driver mutations difficult. Genomic 
sequencing has confirmed a high prevalence of difficult to 
target Tp53 and retinoblastoma 1 (RB1) inactivation muta-
tions. Next-generation sequencing (NGS) has been applied 
to the SCLC genome in hopes of identifying new therapeutic 
targets, and recent work has showcased the identification of 
significantly mutated genes in SCLC cell lines. These aberra-
tions include genetic alterations affecting histone-modifying 
enzymes CREB binding protein (CREBBp), E1A binding pro-
tein p300 (Ep300), and LFF as well as pTEN mutations, FGFR1 
and SOX2 amplification. Recent work on SOX2 demonstrates 
the prevalence of SOX2 amplification in SCLC cell lines with 
expression of SOX2 strongly correlated with increased gene 
copy number and clinical stage leading the authors to postulate 
if SOX2 is a genuine SCLC driver mutation.23,24
EPIGENETIC THERAPY IN THE  
TREATMENT OF LUNG CANCER
The contributions of epigenetic dysregulation to car-
cinogenesis through aberrant DNA methylation and altered 
chromatin configuration continue to be expanded.25 The can-
cer epigenome contains a variety of tumor-specific alterations 
which define subgroups of disease, alter transcriptional pat-
terns, and may reflect therapeutic sensitivities.26–28
Recent genomic sequencing efforts have further under-
scored the inextricable connections between genetic and epi-
genetic mechanisms of carcinogenesis, including alternative 
mechanisms leading to loss of individual tumor suppressor 
gene function and cooperation of defects affecting key sig-
naling pathways. A signature example in lung cancer is the 
CDKN2A locus, encoding both the p16 tumor suppressor (a 
key regulator of cell-cycle progression from G1- to S-phase) 
and alternate reading frame (ARF) (which can sequester 
mouse double minute 2 homolog (MDM2) leading to stabili-
zation of the tumor suppressor p53). Comprehensive genomic 
analysis of squamous cell lung cancers by the Cancer Genome 
Atlas (TCGA) Research Network has demonstrated CDKN2A 
loss of function in the large majority of cases, the most com-
mon mechanisms being homozygous deletion in 29%, site-
specific promoter hypermethylation leading to gene silencing 
in 21%, and missense or truncating mutation in 18%.27
The TCGA has also demonstrated, across tumor types, 
high rates of genetic alterations in key epigenetic regulators. 
These include members of the mixed-lineage leukemia gene 
family of histone methyltransferases, mutated in 20% and 18% 
of squamous and nonsquamous lung cancers, respectively.29 
Chromatin-modifying enzymes which add and remove his-
tone modifications, termed “writers” and “erasers”, affect the 
state of chromatin compaction of DNA making it more or less 
accessible for the transcription of genes which play various 
roles in the transformation of a cancer cell (Fig. 2). Beyond 
the vast changes in DNA methylation that characterize can-
cer, these enzymes contribute to an altered landscape of tran-
scriptional regulation not only in the hematologic malignancies 
for which epigenetic therapy has found early success but also 
in a broad range of solid tumors including lung cancers.25,29 
Mutations of the isocitrate dehydrogenase genes, found across 
many tumor types, most notably gliomas and sarcomas but also 
including a small percentage of lung cancers, result in a CpG 
island methylator phenotype with therapeutic implications.29,30 
Multiple CpG island methylator phenotype–like states have 
been described, and the molecular abnormalities responsible 
for these phenotypes are beginning to be defined; to date, these 
include alterations in genes affecting the metabolism of meth-
ylated cytosines and mutations in DNA methyltransferases.30,31
Historically, identification and demonstration of re-
expression of individual tumor suppressor genes have provided 
the rationale for the clinical development of DNA hypomethyl-
ating agents and histone deacetylase inhibitors in various hema-
tologic malignancies.32 In fact, of course, hundreds of genes are 
affected by these therapies. Many of the described “hallmarks of 
cancer,” broad programs of normal cellular functions subverted 
during carcinogenesis, are altered by epigenetic reprogram-
ming.33 Epigenetically directed therapies have the potential to 
concurrently affect multiple relevant pathways critical to can-
cer proliferation, survival, and metastatic capacity. Site-specific 
hypermethylation of promoters for genes controlling stem cell 
maturation has been implicated as a mechanism contributing to 
replicative immortality and clonogenic potential in cancer.34,35 
promoter demethylation by DNA methyltransferase inhibitors 
such as azacitidine can markedly reduce replicative capacity in 
cancer cell lines, associated with reversal of a program of can-
cer-specific changes in methylation.36 Mutations in epigenetic 
regulators such as the polycomb-repressive complex protein 
polycomb ring finger oncogene BMI-1 (BMI-1) and the his-
tone methyltransferase EZH2 can enhance clonogenic potential 
of cancer cells.35 In addition, genetic alterations of chromatin 
regulatory genes with established roles in proliferation, inhibi-
tion of apoptosis and senescence, and promotion of genomic 
instability have been described.35
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In addition to affecting key elements of carcinogenesis, 
epigenetic therapy may have a role in the treatment of acquired 
resistance to mutationally targeted therapy. For example, inhi-
bition of the histone demethylase KDM5A has been shown 
to preferentially eliminate clonogenic survivors to EGFR TK 
therapy in EGFR-mutant NSCLC cell lines.37
Although epigenetic therapy regimens using DNA 
hypomethylating agents or histone deacetylase inhibitors have 
become standard-of-care therapies in myelodysplastic syn-
drome and peripheral T-cell lymphoma, these treatments have 
only begun to be clinically investigated in lung cancer or other 
solid tumors. Combinatorial epigenetic therapy consisting of 
the DNA hypomethylating agent azacitidine and the histone 
deacetylase inhibitor entinostat has been shown to result in rare 
objective responses in lung cancer.38 Data from this initial study 
suggest that combinatorial epigenetic therapy may prime lung 
cancers for improved responses to subsequent therapy, nota-
bly including immunotherapy. preclinical models suggest that 
multiple pathways down-regulated in tumors as a mechanism of 
immune escape and evasion may be re-expressed in response to 
epigenetic therapy and may augment the effectiveness of pro-
grammed death 1 (pD-1) immune checkpoint blockade.39 Thus 
epigenetic therapy may prime tumors to respond to immunother-
apeutic strategies by overcoming tumor mechanisms including 
increased antigen presentation, up-regulation of programmed 
death receptor ligand 1 (pD-L1) expression, and augmentation 
of interferon and cytokine signaling within the tumor.40
In addition to next-generation hypomethylating agents 
and histone deacetylase inhibitors, there are a host of novel 
epigenetic therapies targeting chromatin modifying enzymes 
now being translated into clinical testing in lung cancer and 
other solid tumors. EZH2 inhibitors are currently in early 
FIGURE 2.  Chromatin-modifying enzymes. MEK, mitogen-activated protein kinase kinase; ERK, extracellular signal–regulated 
kinase; PHD, plant homeodomain; PI3K, phosphatidylinositol 3-kinase; PWWP, proline-tryptophan-tryptophan-proline.
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phase clinical development and may be of relevance in the 
treatment of lung cancers including SCLCs, in which EZH2 
seems to be frequently overexpressed. A DOT1-like his-
tone H3K79 methyltransferase inhibitor is being developed 
for acute leukemias defined by alterations in mixed-lineage 
leukemia, a gene family of histone methyltransferases also 
commonly mutated or otherwise genetically altered in lung 
cancer. Beyond targeting chromatin-modifying enzymes that 
write or erase histone marks, bromodomain and extra-termi-
nal histone-binding proteins possess what may be termed a 
“reading” function focused on histone acetylation; trials of 
inhibitors of the protein–protein interaction have been initi-
ated in SCLC.41–43 The evolving knowledge of the prevalence 
and array of identifiable defects in chromatin regulators and 
DNA-methylation phenotypes suggests a large number of 
potential targets and strategies for epigenetic therapy beyond 
those which have formed the basis of much clinical investiga-
tion of epigenetic therapies to date. Thoracic oncologists can 
expect an expanding portfolio of novel epigenetically targeted 
agents with potential for clinical application to lung cancer 
during the next several years.
EGFR MUTATION–POSITIVE NSCLC
The approach toward lung cancer therapeutics has under-
gone a major paradigm shift in the last 10 years. The impetus 
to move toward larger and more frequent biopsies and perform 
upfront genotyping at the time of diagnosis came in large 
part with the recognition that between 10% and 20% of U.S. 
lung cancer patients had tumors carrying an EGFR mutation, 
a biomarker of oncogene addiction that correlates strongly 
with response to EGFR TKIs.44 There are several subtypes 
of EGFR mutations, but the two most frequent, L858R and 
del19, comprise 90% of the cases and are also the most tightly 
associated with robust response to therapy.45 In this review, 
L858R and del19 mutations will be collectively referred to as 
“common mutations.” We will review the current treatment 
recommendations for EGFR-mutant patients and the pivotal 
studies that shape the basis for the recommendations.
Advanced-Stage Disease: First Line
When EGFR mutations were first discovered, several sin-
gle-arm phase II studies were quickly performed confirming that 
patients with advanced lung cancer and common EGFR muta-
tions did very well with first-line gefitinib and erlotinib therapy, 
with response rates (RRs) of 60% to 75% and median progres-
sion-free survival (pFS) of approximately 9 to 10 months.46–48 
Although these results were two-to-three fold better than what 
was achieved with the current standard-of-care platinum-dou-
blet chemotherapy regimens, there was still some skepticism 
about whether a randomized trial would favor an EGFR TKI or 
not because EGFR-mutant patients seemed to do better on che-
motherapy than EGFR wild-type patients. However, this debate 
was settled when the IpASS study was published.
Iressa pan-Asia Study (IpASS) was a large random-
ized trial of approximately 1200 patients done in Asia, where 
EGFR mutations are two to three times more common than 
in western countries.6 All the subjects were nonsmokers with 
adenocarcinoma, both of which are clinical features that have 
been associated with increased incidence of EGFR mutations. 
patients did NOT have to have an EGFR mutation to enter 
the trial, but among the subset that had tissue available for 
EGFR mutation testing, approximately 60% were positive for 
common EGFR mutations. The IpASS design compared first-
line gefitinib with first-line chemotherapy with carboplatin 
and paclitaxel for up to six cycles with a primary end point of 
pFS. The results showed that in the overall intention-to-treat 
population, gefitinib had an improved pFS compared with 
chemotherapy with a hazard ratio (HR) of 0.74 and a 95% 
confidence interval (CI) of 0.65 to 0.85 (Table 2). However, 
when examining the subset of patients with tissue available 
for genotyping, it became clear that the overall positive results 
for gefitinib were exclusively due to the contribution from 
the EGFR-mutant cohort of patients, who had an even more 
impressive pFS benefit from first-line gefitinib (HR, 0.48; 
95% CI, 0.36–0.46). Conversely, the EGFR wild-type patients 
showed that front-line EGFR TKI was a harmful strategy for 
them with HR of 2.85 (95% CI, 2.1–4.0). In addition to a pFS 
benefit, patients with EGFR mutations treated with gefitinib 
had an improved quality of life compared with those treated 
with chemotherapy.49 Hence, practice changed significantly 
with the IpASS publication in two major ways: (1) the impor-
tance of early genotyping was appreciated and giving first-
line EGFR TKIs to patients with EGFR mutations became an 
accepted therapeutic strategy and (2) because the wild-type 
patients did so poorly with first-line gefitinib in lieu of chemo-
therapy, it became obvious that if one did not know the muta-
tion status for a patient, then EGFR TKIs should not be given, 
at least in the first-line setting.
After IpASS, several other randomized trials were 
completed in rapid succession, each confirming similar ben-
efits from first-line gefitinib or erlotinib, primarily for patients 
with common EGFR mutations (Table 2).7,50–53 The European 
Randomized Trial of Tarceva versus Chemotherapy (EURTAC) 
study was especially important from this collection of studies as 
it was the first such trial performed in a western population.52 In 
EURTAC, Spanish and Italian EGFR-mutant patients (common 
mutations only) treated with first-line erlotinib had improved 
pFS compared with investigator-choice chemotherapy (either 
cisplatin/docetaxel or cisplatin/gemcitabine) (HR, 0.37; 95% 
CI, 0.25−0.54). None of the studies examining first-line gefi-
tinib or erlotinib have demonstrated a survival advantage for the 
genotype-directed therapy, presumably because EGFR mutants 
have a very robust RR and pFS when EGFR TKIs are given in 
the second-line or later-line setting and thus allowing them to 
“catch up” to the benefit achieved with first-line therapy.
More recently, two randomized studies were completed 
with the second-generation EGFR TKI afatinib as first-line 
therapy for EGFR mutation–positive patients.54,55 In contrast 
to the first-generation drugs erlotinib and gefitinib, second-
generation EGFR TKIs are “irreversibly binding” meaning 
that instead of adenosine triphosphate (ATp)-competitive 
binding at the receptor, the drug forms a direct chemical cova-
lent bond with the EGFR receptor. In addition, afatinib binds 
all the ErbB receptors, not just EGFR. Lux-lung 3 was a global 
study comparing afatinib with cisplatin/pemetrexed, and Lux-
lung 6 was performed in China only, comparing afatinib with 
S36 Copyright © 2014 by the International Association for the Study of Lung Cancer
Morgensztern et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 1, Supplement 1, January 2015
cisplatin/gemcitabine. Similar to the prior studies, the afa-
tinib trials showed a superior pFS, RR, and quality of life for 
genotype-directed treatment, particularly among the 90% of 
trial participants with common EGFR mutations. As a result, 
afatinb was Food and Drug Administration (FDA) approved in 
2013 as first-line therapy for patients with L858R and deletion 
19 EGFR mutations. At the 2014 American Society of Clinical 
Oncology (ASCO) meeting, we also learned that among exon 
19 deletion mutants, first-line afatinib seems to improve OS 
compared with first-line chemotherapy.56 Although these 
results were from a post hoc subgroup analysis, the survival 
benefit was large (approximately 1 year) and was replicated 
in both Lux-lung 3 and Lux-lung 6 with highly significant p 
values (Table 2). The L858R patients did not have a survival 
advantage with afatinib, similar to the results from other stud-
ies with gefitinib and erlotinib.
Because of this collection of research, the current stan-
dard approach in the Unites States is to test all patients with 
newly diagnosed advanced adenocarcinoma for EGFR muta-
tions and, if positive for a common mutation, to treat with 
either afatinib or erlotinib.57 If patients are symptomatic from 
their cancer and cannot wait for the results of mutation test-
ing to return, chemotherapy should be started as EGFR TKIs 
should only be given in the first-line setting to patients known 
to have an EGFR mutation. There are uncommon mutations 
that are still considered sensitizing to EGFR TKIs such as 
L861Q, G719X, and S768I. However, it is important to note 
that the exon 20 insertion/deletion mutations are typically not 
sensitive to erlotinib, gefitinib, and afatinib.58
Advanced-Stage Disease: Special 
Considerations for EGFR-Mutant Patients
There are several considerations in the management 
of EGFR-mutant patients that are unique compared with 
historical approaches for treating lung cancer: (1) When to 
start EGFR TKIs if chemotherapy was given before mutation 
TABLE 2.  Summary of Randomized Trials Examining Genotype-Customized First-Line EGFR TKI Therapy








HR for  
OS (95% CI)
IpASS6,54 Gefitinib 132 71% 9.6 0.48 (0.36–0.64) 21.6 1.00 (0.76–1.33)
Carbo/pac 129 47% 6.3 21.96
WJTOG 34057a Gefitinib 86 62% 9.2 0.49 (0.35–0.71) NR NR
Cis/doce 86 31% 6.3 NR
NEJ 0028 Gefitinib 114 74% 10.4 0.36 (0.25–0.51) 30.5 No ratio provided  
p = 0.31Carbo/pac 114 31% 5.5 23.6
OpTIMALa50 Erlotinib 83 83% 13.1 0.16 (0.10–0.26) NR NR
Carbo/gem 82 36% 4.6 NR
EURTACa51 Erlotinib 86 58% 9.7 0.37 (0.25–0.54) 19.3 1.04 (0.65–1.68)
Carbo or cis/gem 
or doce
87 15% 5.2 19.5
Lux-Lung 352 Afatinib 230 69% 11.1 0.58 (0.43–0.78) 28.2 0.88 (no CI provided)
Cis/pem 115 44% 6.9 28.2
Lux-Lung 3: Afatinib arm,  
common mutations onlya
203 75% 13.6 0.47 (0.34–0.65) 31.5 0.78 (0.58–1.06)
Lux-Lung 3: Cis/pem arm,  
common mutations onlya
104 43% 6.9 28.6
Lux-Lung 3: Afatinib arm,  
exon 19 del only56
112 NR NR 0.28 (0.18–0.44) 33.3 0.54 (0.36–0.79)
Lux-Lung 3: Cis/pem arm,  
exon 19 del only
57 NR NR 21.1
Lux-Lung 653 Afatinib 242 74% 11.0 0.28 (0.20–0.39) 23.1 0.93 (no CI provided)
Cis/gem 122 31% 5.6 23.5
Lux-Lung 6: Afatinib arm,  
common mutations onlya
216 NR 11.0 0·25 (0.18–0.35) 23.6 0.83 (0.62–1.09)
Lux-Lung 6: Cis/gem arm,  
common mutations onlya
108 NR 5.6 23.5
Lux-Lung 6: Afatinib arm,  
exon 19 del only56
124 NR NR 0·20 (0·13 0·33) 31.4 0.64 (0.44–0.94)
Lux-Lung 6: Cis/gem arm,  
exon 19 del only
62 NR NR 18.4
aOnly L858R and del 19 mutants were included in this study.
CI, confidence interval;  EURTAC, European Randomized Trial of Tarceva Versus Chemotherapy; HR, hazard ratio; IpAS, Iressa pan-Asia Study; NEJ, North East Japan; NR, 
no mature data reported; OpTIMAL, Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer; pFS, 
progression-free survival; OS, overall survival; WJTOG, West Japan Thoracic Oncology Group.
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test result availability, (2) Should EGFR TKIs be continued 
beyond progression, and (3) How to work-up EGFR muta-
tion–positive lung cancer with acquired resistance to the first 
EGFR TKI. There are no definitive randomized trials that 
give us direction about these issues, but clinical experience 
is now large and consensus recommendations are emerging. 
For patients who were unable to wait for EGFR mutation test 
results before starting first-line chemotherapy, it is always 
difficult to know when and how to start an EGFR TKI after 
the mutation is discovered. Options range from beginning the 
TKI immediately after the test results returns to not until the 
patient progresses and second-line therapy is indicated. One 
popular approach is to complete four to six cycles of the first-
line chemotherapy (assuming the patient is tolerating therapy 
and is not progressing through it) and then switch to the EGFR 
TKI, similar to a maintenance approach; however, no clinical 
trials have addressed this specific situation.58
A more common question is under what circumstances 
to continue an EGFR TKI when the patient is progressing on 
therapy. The discussion arises because it has been observed 
that even when EGFR mutants are radiographically progress-
ing through an EGFR therapy, removal of that therapy can has-
ten a clinically significant flare in the disease in up to 25% of 
cases, leading to hospitalization and/or death in approximately 
1 week in the initial publication.59 The disease flare is thought 
to be due to a mix of clones within the tumor, some of which 
are still sensitive to the EGFR TKI and remain under control 
even while other clones are growing. Removal of the suppres-
sive TKI can allow many more cells to divide compared with 
keeping the suppressive TKI on board.
EGFR mutants have two distinctive patterns of progres-
sion not historically distinguished in lung cancer treatment 
paradigms: (1) progression in only one site while the rest of 
the disease remains stable, and (2) very slow and indolent pro-
gression in multiple anatomic locations. There is mounting 
evidence suggesting that if progression is only in one loca-
tion, then local treatment (surgery or radiation) followed by 
continued EGFR TKI therapy can yield good outcomes.60,61 
In one study using this approach, EGFR-mutant patients had 
controlled disease for a median of 6 months after the locally 
directed therapy before further progression was noted.60 In 
addition, clinical experience is accumulating supporting the 
notion that patients who are having slow and indolent progres-
sion while on an EGFR TKI can achieve significant additional 
time on therapy after meeting Response Evaluation Criteria 
in Solid Tumors (RECIST) criteria for progression.62,63 One 
single institution experience documented that 88% of EGFR 
patients received ongoing EGFR TKI beyond RECIST-defined 
progression and the median time until a change in therapy was 
necessary from that point was 10 months.63
Once a patient is progressing sufficient to demand a 
change in systemic therapy, there is an additional question of 
whether one should stop the EGFR TKI and switch to chemo-
therapy or continue the EGFR TKI along with adding chemo-
therapy. Again, the observation of a clinically significant flare 
in disease if the EGFR TKI is stopped has fueled interest in 
this question. prospective randomized studies are in process 
which will provide further guidance, but retrospective studies 
suggest that RRs may be higher if the EGFR TKI is continued 
while chemotherapy is added.64
Considering a biopsy at the time of progression on 
the initial EGFR TKI is an emerging standard for EGFR 
mutants.56 Initially this was a maneuver primarily done for 
research purposes to gain a better understanding of the range 
of molecular mechanisms of acquired resistance and to con-
sider customizing clinical trial options for patients. It then 
became appreciated that a small portion of patients would 
have a transformation from adenocarcinoma harboring an 
EGFR mutation to SCLC with the same EGFR mutation as 
an escape mechanism from their EGFR TKI.65,66 This transfor-
mation, although rare, facilitated broader clinical interest in 
repeat biopsies because the biopsy might indicate a new thera-
peutic direction. In the current era, data are rapidly accumulat-
ing that third-generation EGFR TKIs may have high activity 
among those with acquired resistance by virtue of the T790M 
mutation in exon 20, the single mutation that accounts for 
50% to 65% of acquired resistance (see later in the article).67,68 
This provides yet an additional and compelling clinical indica-
tion for biopsy at the time of acquired resistance.
Treatment of Acquired Resistance
Even though initial therapy with an EGFR TKI is quite 
effective, acquired resistance still develops after 10 to 15 
months. When the second-generation EGFR TKIs were devel-
oped, there was great hope that these would be highly effective 
for patients with acquired resistance because laboratory stud-
ies showed that these compounds had a high level of activity 
against T790M in vitro.69 Unfortunately, in clinical trials, all 
three second-generation EGFR TKIs tested (neratinib, afa-
tinib, and dacomitinib) have had disappointing results with 
RRs in the single digits.70–72 The explanation behind the dis-
cordant preclinical and clinical results is thought to be that 
the second-generation drugs have a high degree of wild-type 
EGFR potency, therefore dose escalation is limited by rash, 
diarrhea, and other side effects resulting from wild-type 
EGFR inhibition. Hence, in patients, it seems difficult to 
achieve drug concentrations sufficient to inhibit T790M.
The first successful clinical trial for EGFR acquired 
resistance was a phase I trial examining the combination of 
afatinib and cetuximab.73 This trial expanded when activity 
was observed to ultimately include 93 patients. The RR was 
32%, significantly higher than the 7% observed with single 
agent afatinib. However, the toxicity of this regimen is not 
insignificant, with 18% of patients having grade 3 acneiform 
rash (rash that limits activities of daily living and covers 
>30% of the body surface area). Interestingly, the preclinical 
evidence for this combination suggested that T790M mutants 
would preferentially benefit74; however, the clinical obser-
vation has been that response is roughly equal regardless of 
T790M status.
A new class of third-generation EGFR TKIs have 
recently entered clinical study.67,68 These differ from the prior 
generations of EGRF TKIs because although they have potent 
inhibition of both activating EGFR mutations and T790M, 
wild-type inhibition is close to zero, allowing dose escala-
tion to concentrations that can effectively overcome acquired 
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resistance. Two compounds have had mature results presented 
in abstract form thus far, CO-1686 and AZD9291. Both have 
demonstrated RRs of approximately 60% among those with 
biopsy-proven T790M. Mature pFS is not yet available, but 
responses appear to be durable for at least 6 months in most 
patients in the preliminary data. As suspected, rash and diar-
rhea are extremely uncommon during therapy with third-gen-
eration EGFR TKIs. CO-1686 causes hyperglycemia, which is 
typically controlled with oral medications.
Early-Stage Disease
Whenever there is a successful strategy for treating 
advanced-stage disease, such as EGFR TKIs for patients with 
EGFR mutations, there is interest in moving the therapy from 
late-stage disease to early-stage disease with the hope of increas-
ing cure rates. Studies are just beginning that will look at incor-
poration of EGFR TKIs into multimodality therapy for stage 
III disease. However, two studies have been completed offer-
ing preliminary data about adjuvant erlotinib. The Surgically 
resected EGFR mutant lung cancer with adjuvant erlotinib can-
cer treatment (SELECT) study was a single-arm multicenter 
study of 2 years of adjuvant erlotinib for patients with common 
EGFR mutations.75 One hundred patients were treated (stage I 
n = 45, stage II n = 27, and stage III n = 28) and the primary 
end point of 2-year disease-free survival (DFS) was 89% (by 
stage I: 96%, stage II: 78%, and stage IIIA: 91%), which was 
significantly improved compared with the predefined historical 
control 2-year DFS for EGFR mutants followed with observa-
tion alone. In addition, after a median duration of follow-up of 
more than 3 years, of the 29 patients that recurred, only four 
recurred while one erlotinib and 25 recurred after erlotinib was 
completed, raising speculation that duration of therapy may be 
important. The Surgically resected EGFR mutant lung cancer 
with adjuvant erlotinib cancer treatment (RADIANT) study was 
a randomized study of 2 years of adjuvant erlotinib versus pla-
cebo that enrolled a broader population of lung cancer patients 
among which 16% harbored EGFR mutations.76 Although the 
overall study was negative, the subgroup analysis of EGFR 
mutants suggested that erlotinib provided a DFS advantage 
with HR of 0.61 (95% CI, 0.38–0.98), but no OS advantage in 
this preliminary study. A more definitive prospective random-
ized trial including only EGFR mutants and powered to exam-
ine OS is set to begin this year.
HER-2/3–POSTIVE NSCLC
The Role of HER2 and HER3 in NSCLC
HER2 and HER3 (also known as ERBB2 and ERBB3, 
respectively) are members of the HER/ERBB RTK family, 
which also includes EGFR and HER4. Although these recep-
tors all mediate cell proliferation and survival through down-
stream MApK and pI3K pathways, they vary with regard to 
the ability to bind ligand and the presence of an active TK 
domain. For example, HER2 has no known high-affinity ligand 
and therefore uses homo- or heterodimerization for activation, 
and HER3 has no TK activity and relies on heterodimerization 
to induce downstream signaling. The most powerful signaling 
heterodimer is that of HER2 and HER3, which can function 
as an oncogenic unit.77
Oncogenic HER2 kinase domain mutations were first 
reported in NSCLC in 2004.78 Since that time, several stud-
ies have found the rate of kinase domain HER2 mutations in 
NSCLC to be approximately 2% to 4%.79–81 These mutations 
are most commonly in-frame insertions in exon 20 with dupli-
cation of amino acids YVMA at codon 775; infrequently, inser-
tions in other codons or point mutations can be found that lead 
to constitutive activation of downstream pathways resulting in 
cell growth and survival. More recently, extracellular domain 
mutations were detected in HER2 and found to be oncogenic, 
including a S310F mutation in exon 8 detected in one of 188 
lung adenocarcinomas,82 a S310Y mutation in one of 63 squa-
mous cell lung cancers,83 and 1 S310F and 1 S310Y muta-
tion in 258 lung adenocarcinomas sequenced by the Cancer 
Genome Atlas Network. Across these studies, the frequency of 
extracellular domain mutations appears to be less than 1%.
In contrast to HER2, there have been no reports of 
mutations in the HER3 gene. However, HER3 has been impli-
cated as an escape mechanism for drugs that inhibit signaling 
through EGFR and HER2.84,85 Attempts at therapeutically tar-
geting both HER2 and HER3 are ongoing.
Clinical Features of Patients with 
HER2-Mutated NSCLC
patients with HER2-mutant NSCLC have distinct clini-
copathologic characteristics, similar to those whose tumors 
harbor EGFR mutations. In the largest reported study of 65 
patients with HER2-mutant NSCLC to date, the median age 
of diagnosis was 60.4 years (range, 31–86), 69% were female, 
52% were never-smokers, and all tumors were adenocarcino-
mas.81 Although HER2 mutations are relatively rare in lung 
cancer, the rate of detection can be enriched by testing never-
smoker patients with adenocarcinoma or adenosquamous his-
tology without an EGFR mutation, in which case the frequency 
is approximately 14%.79 HER2 mutations are mutually exclu-
sive with point mutations in EGFR, KRAS, BRAF, neuroblas-
toma RAS viral (v-ras) oncogene homolog (NRAS), PIK3CA, 
MEK1, and AKT, as well as rearrangements in ALK.80
Preclinical and Clinical Data for 
Therapeutics Targeting HER2 and HER3
Both small molecular inhibitors and monoclonal anti-
bodies targeting HER2 are under investigation. Currently, there 
are limited data for patients treated on prospective clinical tri-
als; however, preclinical studies and retrospective data from 
patients treated with off-label, commercially available agents 
show promise in targeting HER2 in those with HER2-mutant 
NSCLC. Below are several compounds under investigation.
Trastuzumab
In contrast to breast cancer, HER2 overexpression or 
amplification does not predict for benefit from trastuzumab in 
lung cancer. However, the presence of a HER2 mutation may be 
a predictive biomarker for response to trastuzumab in NSCLC. 
In a retrospective study of 16 patients with HER2-mutant 
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NSCLC, a total of 22 anti-HER2 treatments were assessed.81 Of 
the patients who received trastuzumab-based regimens (trastu-
zumab combined with carboplatin, paclitaxel, carboplatin/pacli-
taxel, vinorelbine, or docetaxel), the RR was 60% (nine of 15 
regimens tested) and disease control rate was 100%. One patient 
received trastuzumab alone and had a partial response (pR).
Afatinib
Afatinib is an irreversible small molecular inhibitor of EGFR 
and HER2 that is approved for use in the first-line setting for 
patients with EGFR-mutant NSCLC. In lung cancer cell lines 
harboring a HER2 insertion mutation in the TK domain, afatinib 
was effective at inhibiting survival, whereas erlotinib was not.86 
Interestingly, afatinib was also effective at inhibiting survival in 
cell lines transformed with the HER2 extracellular domain muta-
tion.82 The clinical activity of afatinib in HER2-mutant NSCLC 
has been evaluated in the same retrospective study discussed 
above.81 Three patients who had progressed after receiving trastu-
zumab-based therapy were treated with afatinib, which resulted 
in 100% disease control rate (one pR and two stable disease 
[SD]). In the only prospective study with afatinib in this popula-
tion, five patients with NSCLC harboring a HER2 kinase domain 
mutation were treated with afatinib, followed by the option to add 
weekly paclitaxel at 80 mg/m2 to afatinib at progression.87 Of the 
three patients evaluable for response (two patients withdrew early 
due to toxicity), two had a pR to afatinib alone and one had SD 
with afatinib and a pR once paclitaxel was added.
Dacomitinib
Dacomitinib is an irreversible pan-HER TKI. A phase II 
study including patients with NSCLC and HER2 amplification 
or mutation with any number of prior lines of therapy treated 
patients with dacomitinib 45 or 30 mg with the option to esca-
late to 45 mg once daily.88 Of the 16 evaluable patients in the 
HER2 cohort, there were two with a pR, both of whom had 
a HER2 mutation. Final results from this study are pending.
Neratinib
preclinical mouse models of HER2-mutant lung can-
cer have demonstrated that HER2 inhibition plus mammalian 
target of rapamycin (mTOR) inhibition results in significant 
tumor shrinkage over either alone.89 On the basis of this and 
other preclinical data, the combination of neratinib, an irrevers-
ible pan-HER small molecule inhibitor, and temsirolimus, an 
mTOR inhibitor, was studied in a phase I trial including patients 
with multiple tumor types.90 Six patients of the 60 on the trial 
had HER2-mutant NSCLC. Among them, two had a pR (one 
of whom had prior trastuzumab) and the remainder had an SD.
MM-111
MM-111 is a bispecific fully human antibody targeting 
HER2 and HER3. In preclinical studies of HER2-overexpressing 
cancer cells, MM111 inhibits cell proliferation, particularly 
when used in combination with other HER2 inhibitors such 
as trastuzumab.91 A phase I trial in multiple tumor types with 
HER2 positivity is testing MM-111 combined with various 
HER2-targeted agents and chemotherapeutics to determine the 
maximally tolerated dose, safety, and efficacy. This drug has not 
yet been tested in patients with HER2-mutant NSCLC.
MEHD 7945 A
In contrast to the previously discussed compounds, MEHD 
7945 A does not target HER2, but instead is a dual-action human 
immunoglobulin G1 (IgG1) monoclonal antibody that targets 
EGFR and HER3. In cell lines and xenograft models of tumors 
resistant to the EGFR inhibitors cetuximab or erlotinib, MEHD 
7945 A was able to overcome resistance and inhibit tumor 
growth.92 Clinically, the safety and activity of MEHD 7945 A 
were studied in a phase I trial in multiple tumor types.93 Nine 
patients with NSCLC were included, of which two had SD as 
their best response. The final report from this study is pending.
MM-121
Unique compared with the other drugs discussed here, 
MM-121 is a monoclonal antibody that only targets HER3. It 
is being developed in combination with other targeted agents 
or chemotherapeutics, which is not surprising given the lack 
of known alterations in HER3 in human cancers. Specifically, 
MM-121 is being tested in combination with erlotinib, with 
early signals of clinical benefit in patients with EGFR-mutant 
NSCLC and erlotinib resistance.94
ALK-POSITIVE NSCLC
Chromosomal rearrangements of ALK are present in 
3% to 7% of NSCLC. The resulting ALK fusions, such as 
EML4-ALK, function as potent oncogenic drivers and lead 
to a state of oncogene addiction. In the clinic, this phenom-
enon underlies the marked responsiveness of ALK-positive 
tumors to small molecule ALK TK inhibition. Crizotinib, a 
multitargeted TKI of ALK, ROS1 and cMET, was the first 
ALK inhibitor tested in the clinic and helped to establish 
ALK as a therapeutic target in NSCLC.12 To date, nine other 
ALK inhibitors have now entered clinical development, with 
promising early results in both crizotinib-naive and crizotinib-
resistant disease. In this study, we review the latest data on 
crizotinib and select next-generation ALK inhibitors in TKI-
naive patients with ALK-positive NSCLC.
5.1 Crizotinib
phase I and II studies have shown that crizotinib is highly 
active in patients with advanced, ALK-positive NSCLC. In 
the phase I trial (pROFILE 1001), the objective RR (ORR) 
among 143 evaluable patients was 61% and median pFS 
was 9.7 months.95 Updated results from the phase II study of 
crizotinib (pROFILE 1005) were recently reported in the U.S. 
FDA label. Among 765 patients with advanced, ALK-positive 
NSCLC, the ORR was 48% and median duration of response 
was 11 months;96 the follow-up of these phase II patients was 
too short to evaluate pFS. On the basis of RRs observed in the 
phase I and II studies, along with its favorable side effect pro-
file, crizotinib was granted accelerated approval by the FDA 
in August 2011 for patients with advanced, ALK-positive 
NSCLC. This approval occurred almost exactly 4 years after 
the first report of ALK rearrangements in NSCLC.97
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Recently, the results of the first prospective, randomized 
phase III trial comparing crizotinib with standard chemother-
apy in advanced, ALK-positive NSCLC (pROFILE 1007) were 
reported.11 In this study, 347 ALK-positive patients who had 
failed one prior platinum-based chemotherapy regimen were 
randomized 1:1 to receive either crizotinib as their second-line 
therapy, or pemetrexed or docetaxel chemotherapy. Compared 
with standard single-agent chemotherapy, treatment with 
crizotinib resulted in a significantly longer pFS and a tripling 
of the ORR. The median pFS with crizotinib was 7.7 months 
by independent radiology review compared with 3 months 
with chemotherapy. Consistent with previous single-arm stud-
ies, the RR with crizotinib was 65%, as opposed to 20% with 
chemotherapy, thus confirming the significant antitumor activ-
ity of crizotinib in advanced ALK-positive NSCLC.
In this study, crizotinib was more active than either 
pemetrexed or docetaxel chemotherapy in ALK-positive 
NSCLC.11 Consistent with previous studies in unselected 
patients with advanced NSCLC, the efficacy of second-line 
docetaxel in ALK-positive NSCLC was minimal, with a 
median pFS of 2.6 months and an ORR of 6.9%.98 In contrast, 
pemetrexed showed greater activity than expected based on 
previous second-line studies.99 Median pFS was 4.2 months 
in ALK-positive patients as compared with 3.5 months in 
unselected NSCLC patients with adenocarcinoma histol-
ogy. The RR to pemetrexed was also higher in this study at 
29.3% as compared with 12.8% in the general population of 
lung adenocarcinomas.100 Although these findings suggest that 
patients with ALK-positive NSCLC may be more responsive 
than average to pemetrexed-based chemotherapy, the benefit 
of pemetrexed seems to be less than that originally suggested 
by small retrospective studies,101,102 and importantly, signifi-
cantly less than that with crizotinib.
In a prespecified interim analysis, OS was found to be 
similar between the crizotinib and chemotherapy arms with a 
median OS of 20.3 and 22.8 months, respectively.11 This analy-
sis was immature with a total of 96 deaths (40% of the required 
events) and censoring of more than 70% of patients in either 
treatment arm. In addition, the analysis was likely confounded 
by the high crossover rate of patients in the chemotherapy group. 
Approximately 90% of patients who were treated with chemo-
therapy and had disease progression crossed over to receive 
crizotinib. This issue has similarly complicated the analysis of 
OS in multiple randomized phase III studies of EGFR TKIs in 
advanced EGFR-mutant NSCLC. In these studies where the 
crossover rate from chemotherapy to targeted therapy ranged 
from 64% to 95%, no difference in OS was demonstrated despite 
substantial improvements in pFS with the targeted therapy.
Several important issues regarding the role of crizotinib 
in ALK-positive NSCLC remain to be addressed. In many 
countries, crizotinib is an approved therapy for patients with 
advanced, ALK-positive NSCLC with no requirement for 
prior treatment. As a result, crizotinib can be prescribed as 
first-line therapy. Although the first-line use of EGFR TKIs 
in advanced EGFR-mutant NSCLC has been established 
in multiple randomized phase III studies, there is limited 
data on the use of crizotinib in the first-line setting. In the 
original phase I study, there were 24 patients who received 
crizotinib as their first systemic therapy.95 In this small cohort, 
the ORR was 64% and median pFS was 18.3 months, sug-
gesting that first-line crizotinib may be at least equivalent if 
not more effective than crizotinib in the second-line setting 
and beyond. A randomized phase III trial comparing crizo-
tinib with platinum/pemetrexed chemotherapy in newly diag-
nosed, advanced ALK-positive NSCLC (ClinicalTrials.gov 
number, NCT01154140) has recently completed enrollment, 
and results may be reported at ASCO 2014. A similar phase 
III trial in Asia comparing first-line crizotinib with platinum/
pemetrexed chemotherapy in ALK-positive NSCLC patients 
(ClinicalTrials.gov number NCT01639001) is ongoing.
Next-Generation ALK Inhibitors: 
Alectinib and Ceritinib
Alectinib (RO5424802) is a highly potent and selective 
TKI targeting ALK, but not ROS1 or cMET.103 Alectinib was 
first evaluated in a phase I/II study in Japan and enrolled a 
total of 70 Japanese patients with advanced, ALK-positive 
NSCLC who were crizotinib naive.104 In contrast to the 
pROFILE 1001/5/7 studies which used ALK fluorescence 
in situ hybridization (FISH) only, patients were identified as 
ALK-positive using ALK immunohistochemistry (IHC), fol-
lowed by ALK FISH for confirmation. In the phase II portion 
of the study, the ORR with alectinib dosed at 300 mg twice-
daily was remarkably high at 94%. With a median follow-up 
of only 7.6 months, median pFS is not yet known, but durable 
responses exceeding 12 months have been reported.
Similarly, the next-generation ALK inhibitor ceritinib 
(LDK378) has also demonstrated high RRs in crizotinib-naive 
ALK-positive NSCLC. In preclinical studies, ceritinib is also 
more potent and selective than crizotinib, targeting ALK and 
ROS1 but not cMET.105 In a global phase I study, ceritinib 
was highly active in patients with advanced, ALK-positive 
NSCLC.106 Among 34 patients who had not received an ALK 
inhibitor and who received ceritinib at doses of 400 mg or 
higher, the ORR was 62%, and median pFS was 10.4 months. 
Of note, in contrast to the phase I study of alectinib, this study 
included both Asian and white patients. In addition, the ceri-
tinib study required only ALK FISH testing to demonstrate 
ALK rearrangement, as opposed to both ALK IHC and ALK 
FISH. Thus, these two factors, ethnicity and diagnostic testing, 
could explain the differences in efficacy seen between alec-
tinib and ceritinib in the TKI-naive ALK-positive population.
ROS1-, RET-, AND NTRK1-POSITIVE NSCLC
Biology
Gene fusions result from large-scale inter- or intrarear-
rangements or chromosomal deletions that join pieces of two 
disparate genes and result in chimeric messenger RNA tran-
scripts and proteins. The gene fusions described here contain 
sequences from the 5' region of an unrelated partner gene and 
the 3' region of genes encoding RTKs: ROS1, RET, and neu-
rotrophic tyrosine kinase, receptor, type 1 (NTRK1). These 
gene fusions always have an intact kinase domain encoded 
by the 3' gene region, but contain varying 5' sequences from 
other genes. These partner genes typically provide two critical 
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components: a promoter that allows sufficient transcription 
of the novel gene and sequences that encode oligomerization 
domains. ROS1, RET, and transforming tyrosine kinase pro-
tein (TRKA) (encoded by the NTRK1 gene) are not highly 
expressed in most lung adenocarcinomas, but their upstream 
partner joins a promoter that drives sufficient expression in the 
tumor cell.108–110 The typical mode of activation for these RTKs 
cannot occur because they lack the extracellular domains har-
boring the ligand-binding domain; however, the oligomeriza-
tion domain, for example coiled-coil domains encoded by 
the partners kinesin family member 5B (KIF5B), coiled-coil 
domain containing 6 (CCDC6), ezrin (EZR), tropomyosin 3 
(TpM3), and myosin phosphatase Rho interacting protein 
(MpRIp) facilitate dimerization of the fusion protein.97,111,112 
It is currently unknown whether different fusion partners, 
which can target the fusion proteins to different cellular com-
partments, induce differential tumor behavior, including drug 
sensitivity.113 Activation of the kinase domain initiates a down-
stream signaling cascade that ultimately activates MApK and 
AKT signaling, which leads to cellular proliferation among 
other tumorigenic properties.112,114,115 This dominant signaling 
role makes targeted inhibition of these oncogenes an attractive 
therapeutic strategy (Fig. 3).
Incidence
Multiple studies have investigated the incidence of the 
oncogenic fusions using a variety of techniques, including 
FISH, IHC, NGS of RNA and DNA, and polymerase chain 
reaction; however, an approved companion diagnostic is not 
yet available for these oncogenes.108,111,112,114,116–118 Typically, 
these oncogene fusions do not overlap with other dominant 
oncogenes, but unbiased studies have demonstrated overlap 
of ROS1 fusions and EGFR, KRAS, and BRAF mutations, 
similar to dual oncogenes observed in ALK-positive cases.117–
122 The incidence of ROS1, RET, and NTRK1 gene fusions 
seems to be in the range of 1% to 3% although the reported 
incidence is higher in studies using enriched cohorts (i.e., 
negative for other oncogenes).108,111,112,114,116–118 Although asso-
ciations have been drawn with age, sex, and smoking history, 
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thus these factors should not be used as criteria for selection 
of patients to undergo testing.111,112,114,116,123,124 Although these 
gene fusions are widely associated with adenocarcinoma his-
tology, this is not an ideal selection criteria as squamous cell 
and other histologies have been associated with ROS1, RET, 
and NTRK1 fusions.108,116,117,125,126
ROS1, RET, and NTRK in Other Disease Types
Although these oncogenic fusions occur infrequently 
in lung cancer, interest in these targets is bolstered by their 
occurrence in other malignancies. ROS1 has been detected 
in gastric cancer, colorectal cancer, Spitzoid neoplasms, and 
numerous others.113,119,127,128 RET fusions have long been iden-
tified in papillary thyroid cancer but have also been identi-
fied in chronic myelomonocytic leukemia (CMML) and 
others.128–130 An oncogenic NTRK1 fusion was first detected 
in a colorectal cancer specimen, later found to be prevalent 
in papillary thyroid cancers, and now identified in multiple 
other tumor types.128,129,131–133 Many TRKA inhibitors have 
activity against two homologous RTKs, transforming tyrosine 
kinase protein B (TRKB) (NTKR2), and transforming tyro-
sine kinase protein C (TRKC) (NTRK3). These genes are also 
involved in gene fusions across multiple cancer types, perhaps 
broadening the appeal of these pan-TRK inhibitors.134–137
INHIBITORS OF ROS1, RET, AND TRK.
ROS1
Crizotinib (pfizer) has been approved for use in ALK-
positive NSCLC. ROS1 has high homology to ALK and 
many ALK inhibitors also display ROS1 inhibition.113 An 
expanded phase I trial is the first trial to report clinical out-
comes of ROS1-positive NSCLC patients treated with crizo-
tinib (NCT00585195). The most recent update of 35 patients 
demonstrated an ORR of 60% and a 6-month pFS rate of 
76%, very similar to studies of the same drug in ALK-positive 
NSCLC patients.95,138 Foretinib (XL-880, GlaxoSmithKline) 
is a multikinase inhibitor with activity against ROS1, as well 
as RET, MET, AXL receptor tyrosine kinase (AXL), and other 
kinases, that has a planned ROS1 cohort in an upcoming clini-
cal trial (NCT01068587).139 Ceritinib (LDK378, Novartis) is a 
potent second-generation ALK inhibitor that displays weaker 
ROS1 inhibition105; however, this drug is not currently in clini-
cal trials enrolling ROS1-positive NSCLC patients. Ap26113 
(Ariad) is currently in clinical trials for ALK-positive NSCLC 
and also has activity against ROS1 but is currently not yet 
enrolling ROS1-positive NSCLC patients (NCT01449461). 
pF-06463922 (pfizer) is a next-generation ALK/ROS1 inhibi-
tor that is currently enrolling crizotinib-naive or TKI-resistant 
ROS1 patients (NCT01970865).140
RET
Multiple RET inhibitors are undergoing clinical trials 
in RET-positive NSCLC patients, and many of these drugs are 
multikinase inhibitors. A clinical trial of cabozantinib (XL184, 
Exelixis), a RET inhibitor (in addition to MET and vascular 
endothelial growth factor receptor 2 [VEGFR2]) is currently 
accruing RET-positive NSCLC patients (NCT01639508). 
Early results from this trial demonstrated confirmed pRs in 
two patients and prolonged SD (31 weeks) in a third patient 
demonstrating early clinical activity of this RET inhibitor in 
RET gene fusion positive patients.141 A phase II clinical trial 
of vandetanib (AstraZeneca), a dual RET and EGFR inhibi-
tor, in RET-positive NSCLC is currently accruing patients 
(NCT01823068). A patient treated off-protocol with vandetanib 
300 mg once-daily showed a clinical response.142 An additional 
patient treated with off-protocol vandetanib showed prolonged 
SD of 6 months on drug.143 Lenvantinib (E7080, Eisai) is multi-
kinase inhibitor (VEGFR1-3, fibroblast growth factor receptors 
1-3 [FGFR1-3], stem cell factor receptor [SCFR], and platelet 
derived growth factor receptor [pDGFR]) with activity against 
RET and is currently enrolling patients in a phase II clinical 
trial (NCT01877083).144 Clinical trials of ponatinib (Ap24534, 
Ariad), a multikinase inhibitor with RET activity, in RET-
positive NSCLC are planned (NCT01935336).145,146 Sunitinib 
(pfizer) is another multikinase inhibitor currently in a phase II 
clinical trial of never smokers with lung adenocarcinoma and 
has a secondary end point to evaluate benefit in patient with 
RET gene fusions (NCT01829217).
TRK
LOXO-101 (Loxo) is a selective pan-TRK inhibitor 
(TRKA, TRKB, and TRKC) that is planned to shortly enter 
first in man phase I clinical trials. RXDX-101 (Ignyta) is a pan-
TRK inhibitor that also has ALK/ROS1 activity with reported 
central nervous system penetration and is currently in phase 
I clinical trials. TSR-011 (Tesaro) is an ALK inhibitor with 
approximately 10 selectivity over the TRK family of RTKs 
and is currently in a phase I clinical trial (NCT0204848).147 
pLX7486 (plexxikon), a pan-TRK inhibitor with additional 
activity against Fms, is currently in clinical trials as a single 
agent and in combination with chemotherapy in patients with 
solid tumors (NCT01804530). This study will also evaluate 
cancer-related pain as TRKA signaling can modulate pain: 
Mutations in the NTRK1 gene are the cause of the autosomal 
recessive syndrome of congenital insensitivity to pain with 
anhydrosis.148 A major focus of next-generation ALK inhibi-
tors has been to improve CNS penetration to more effectively 
treat the brain metastases that occur frequently in patients dem-
onstrating disease progression on crizotinib149; however, CNS 
penetration may not be a desired effect of pan-TRK inhibitors. 
Inhibition of TRKB has been linked to ataxia and other serious 
neurologic side effects, mimicking the phenotype of the mutant 
stargazer (stg) mice, which demonstrate ataxia and lack brain-
derived neurotrophic factor, the TRKB cognate ligand.150,151
Resistance
Resistance mechanisms to cognate inhibitors of ROS1 
are similar to mechanisms of drug resistance observed for 
tumors bearing ALK fusions or EGFR mutations. The first 
described mechanism of resistance was a patient with a ROS1 
kinase domain mutation.152 This mutation, G2032R, is analo-
gous to the ALK G1202R and adjacent to the D1203N and 
S1206Y mutation located at the solvent front; all these muta-
tions induce resistance to crizotinib.153–155 preclinical data 
suggests that foretinib and pF-06463922 can inhibit ROS1 
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G2032R and that Ap26113 can overcome the predicted ROS1 
gatekeeper mutation, L2026M.139,140,156 Resistance mecha-
nisms to RET inhibitors have yet to be described in NSCLC 
patients; however, ponatinib has demonstrated activity against 
oncogenic RET carrying substitutions at the predicted gate-
keeper residue, V804.145,146 TRKA harbors a bulky tyrosine 
residue at the conserved gatekeeper position perhaps making 
this position a less likely site of mutation to decrease inhibitor 
binding. Bypass signaling has also recently been described in 
a ROS1-positive cell line model of drug resistance. The lung 
adenocarcinoma cell line with SLC34A2-ROS1, HCC78, 
with in vitro induced resistance to a ROS1 kinase inhibitor, 
switched oncogene dependence away from ROS1 to EGFR.157 
This mechanism of resistant suggests the need for combina-
tion strategies to prevent or overcome resistance.
BRAF-MUTANT NSCLC
BRAF, an oncogene encoding a RAS-regulated kinase 
that promotes cell growth, has generated recent interest in oncol-
ogy.158,159 The majority of BRAF mutations promote kinase acti-
vation, enhancing the ability of kinase to directly phosphorylate 
MEK.159 The BRAF exon 15 mutation in which glutamine is 
substituted for a valine at residue 600 (V600E) destabilizes 
the inactive kinase conformation, leading to continual down-
stream phosphorylation in the MApK signaling cascade. BRAF 
mutations are found in approximately 50% of melanomas, and 
treatment for metastatic melanoma using selectively targeted 
BRAF V600E inhibitors has elicited high RRs.160 Yet, colorectal 
cancers harboring the same BRAF mutation rarely respond to 
BRAF inhibitor monotherapy.161 Clinical investigation targeting 
specific BRAF mutations in NSCLC is ongoing.
Prevalence of BRAF Mutations in NSCLC
In 2002, two studies identified BRAF mutations in 1.6% 
to 3% of NSCLC.159,162 Based on these findings and improved 
genotyping techniques, a 2011 U.S. study examined tissue 
from 697 patients with lung adenocarcinoma of which BRAF 
mutations in codons V600, D594, and G469 occurred in 3% 
of NSCLC cases.163 An analysis looking at the gene more 
broadly conducted in Italy in 2011 identified BRAF mutations 
in 4.9% of patient cases.164 In contrast to melanoma where 
90% of BRAF mutations are V600E, approximately half of 
the BRAF mutations in the general NSCLC population are 
non-V600E.165 A comprehensive genomic study for squamous 
cell lung cancer identified BRAF mutations in 4% of cases, all 
of which were non-V600E.27 The V600E mutation has been 
associated with a more destructive tumor, with a poor prog-
nosis (significantly shorter DFS and OS).164 V600E mutations 
have been reported as significantly more common in females 
than males (8.6% versus 0.9%) and were less strongly associ-
ated with cigarette smoking.164 BRAF mutations in an Asian 
population were detected at a lower frequency (1.3%).166
Clinical Data with BRAF Inhibitors
Vemurafenib, a V600E BRAF inhibitor used in mela-
noma, has been associated with antitumor activity in NSCLC.167 
Dabrafenib has been more rigorously evaluated. In an interim 
analysis of a single-arm trial, the overall RR for single agent 
dabrafenib was 54%, and it was generally well tolerated.168 As 
a result, the FDA granted breakthrough status to dabrafenib 
for V600E mutation–positive NSCLC in January 2014. During 
a clinical trial of the Src family TKI dasatinib for advanced 
NSCLC, a profound antitumor effect was seen in one patient, 
and that patient was subsequently found to have a kinase-
inactivating non-V600E BRAF mutation, Y472CBRAF.169 When 
studying dasatinib in NSCLC cell lines with an endogenous 
inactivating BRAF mutation, the cell lines experienced senes-
cence, which was reversed with transfection of active BRAF.169
Selected Ongoing Trials with BRAF Inhibitors
Currently, a phase II, nonrandomized, open-label study 
of dabrafenib as a monotherapy and in combination with tra-
metinib, a mitogen-activated protein kinase inhibitor, is recruit-
ing stage IV NSCLC participants with BRAF V600E mutations 
(NCT01336634). A study evaluating dasatinib in subjects with 
advanced cancers harboring a DDR2 mutation or an inactivat-
ing BRAF mutation is currently enrolling (NCT01514864). A 
phase II, open-label, second-line study of GSK1120212, which 
is closed to enrollment, compared trametinib with docetaxel in 
stage IV NSCLC with a mutation in KRAS, NRAS, BRAF, or 
MEK1 gene (Clinicaltrials.gov No.: NCT01362296).
KRAS-MUTANT NSCLC
Biology and Nomenclature
In lung cancer, KRAS (chromosome 12p12.1) is the 
principal member of the Ras family (which also includes 
HRAS [11p15.5] and NRAS [1p13.1]) involved in tumori-
genesis. The HRAS and KRAS genes were initially identified 
from studies of two cancer-causing viruses, the Harvey sar-
coma virus and the Kirsten sarcoma virus. These viruses were 
originally discovered in rats by Jennifer Harvey and Werner 
Kirsten, hence the name Rat sarcoma (Ras).170 NRAS is so 
named for its initial identification in human neuroblastoma 
cells. All RAS proteins undergo complex, multi-step post-
translational modification including farnesylation, geranyl-
geranylation, and palmitoylation.
KRAS activation begins with stimulation of various 
upstream receptors, most EGFR in lung cancer. Adaptor pro-
teins interact with the intracellular domain of EGFR and recruit 
guanine nucleotide exchange factors that interact with RAS to 
promote the exchange of guanosine diphosphate (GDp) for 
guanosine triphosphate (GTp). With binding of GTp, activated 
KRAS phosphorylates downstream signaling cascade pro-
teins until GTp is converted to GDp through a GTpase activ-
ity intrinsic to the Ras family enzymes. The end effect is that 
KRAS kinase and signaling capacity is higher when the enzyme 
is bound to GTp instead of GDp. Key downstream effectors 
include the RAF/ MEK/extracellular signal–regulated kinase 
(ERK) cascade (controlling cellular proliferation), pI3K/AKT/
mTOR cascade (controlling survival), and pathways affecting 
tumor invasion and vesicle trafficking (Fig. 4).
Role in Tumorigenesis
KRAS acquires tumorigenic properties when mutations 
arise that decrease its intrinsic GTpase activity. The resulting 
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RAS proteins are locked in the GTp-bound conformation inde-
pendent of upstream signals. This causes marked up-regulation 
of RAS kinase activity and downstream growth and mitotic 
signaling. Overall, RAS mutations occur in approximately 
30% of all human cancers, with KRAS mutations the most 
common and best characterized.171 KRAS mutations result in 
single amino acid substitutions primarily at residues G12, G13, 
or Q61. In addition to lung cancer, KRAS mutations occur in 
70% to 90% of pancreas cancer, 30% to 40% of colorectal can-
cer, 30% of biliary tract cancer, 20% of melanoma, 15% of 
endometrial cancer, and 15% of ovarian cancer.172
In lung cancer, KRAS mutations occur commonly at 
codon 12 (within exon 2) (>80%), occasionally at codon 13, 
and rarely at codon 61. Approximately 80% of codon 12 muta-
tions are guanine/thymidine (purine for pyrimidine) nucleo-
tide transversions,173 which are considered the characteristic 
mutation related to tobacco smoke exposure. KRAS muta-
tions in lung tumors from never smokers are typically gua-
nine/adenine (G/A) (purine for purine) transversions. The two 
most common mutations in NSCLC, G12C (approximately 
40% of cases), and G12V (approximately 20%), arise from 
guanine/thymidine transversions.174 Other principal mutations 
include G12D (17%), G12A (7%), and G12S (5%).175
Clinical Significance
KRAS mutations occur in approximately 20% to 30% of 
NSCLC.176,177 KRAS mutations occur predominantly in ade-
nocarcinoma histology, have been reported rarely in squamous 
cell carcinoma, but have not been observed in SCLC.178,179 
In contrast to EGFR mutations and ALK and ROS1 fusions 
mutations, KRAS mutations are associated with smoking.180 
Among lifetime nonsmokers with lung cancer, KRAS muta-
tions occur only in 2% to 6% of cases.173,181 KRAS mutations 
are mutually exclusive of EGFR, ALK, and ROS1 aberrations.
The prognostic role of KRAS mutations is not clear. In a 
meta-analysis of 24 studies incorporating various disease stages, 
treatments, and KRAS mutation detection methods, KRAS 
mutations were associated with worse survival (HR, 1.35; 95% 
CI, 1.16–1.56).182 However, in a pooled analysis of 1543 patients 
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mutations), there was no difference in OS between KRAS-
mutant and KRAS wild-type cases.173 No significant benefit from 
adjuvant chemotherapy was noted for wild-type cases or codon 
12 mutations; among the 24 codon 13 mutation cases, adjuvant 
chemotherapy was deleterious (HR, 5.78; 95% CI, 2.06–16.2).
In advanced NSCLC, KRAS mutations predict resis-
tance to EGFR TKIs.181 However, the mutual exclusivity 
of KRAS and EGFR mutations and the strong association 
between EGFR mutations and sensitivity to EGFR TKIs limit 
the clinical utility of KRAS mutations as a selection bio-
marker in current clinical practice. In contrast to colorectal 
cancer, in NSCLC, KRAS mutations are not clearly associ-
ated with resistance to the anti-EGFR monoclonal antibody 
cetuximab.183
Treatment of KRAS-Mutant NSCLC
At the present time, there are no targeted therapies clini-
cally available for NSCLC patients with KRAS mutations. 
High affinity binding to the GTp substrate has hindered the 
development of therapeutic agents that inhibit KRAS directly. 
In late 2013, initial reports of KRAS G12C inhibitors that 
bind to an allosteric site specific to the mutant molecule were 
published,184,185 but such drugs are likely years away from clin-
ical use.
Therapeutic strategies against KRAS-mutant cancers 
that have been investigated clinically include inhibition of 
post-translational modification, inhibition of effector path-
ways, and synthetic lethality.
Post-translational Modification
To date, this strategy has had little clinical efficacy. 
Farnesyl transferase inhibitors have failed to inhibit KRAS 
due to alternative prenylation by geranylgeranyl transferase.186 
Combined farnesyl transferase inhibitors and geranylgeranyl 
transferase inhibitor therapy has been associated with exces-
sive toxicity.187
Effector Pathway Inhibition
Several clinical trials have evaluated MEK inhibition 
alone or in combination with other therapies for KRAS-
mutant lung cancer. In a phase II clinical trial of docetaxel 
± the MEK inhibitor selumetinib (AZD6244; AstraZeneca) 
for previously treated advanced KRAS-mutant NSCLC, selu-
metinib was associated with improved pFS (5.3 versus 2.1 
months; 80% CI, 0.42–0.79; p = 0.14) and a trend toward 
improved OS (9.4 versus 5.2 months; 80% CI, 0.56–1.4; p = 
0.21).15 Another phase II trial randomizing patients to selu-
metinib alone or in combination with erlotinib has completed 
enrollment (NCT01229150). Other MEK inhibitors under 
study specifically in KRAS-mutant NSCLC include MEK162 
(Novartis) combined with erlotinib (NCT01859026) and 
trametinib (GSK1120212; GlaxoSmithKline) monotherapy 
(NCT01362296).
A possible benefit of BRAF inhibition in KRAS-
mutant NSCLC was suggested in the Biomarker-integrated 
Approaches of Targeted Therapy for Lung Cancer Elimination 
trial. In that study, 11 of 14 (79%) patients with KRAS/BRAF 
mutations had disease control at 8 weeks with sorafenib.188 
However, in preclinical models, BRAF inhibitors appear inef-
fective against RAS-mutant cells, paradoxically potentiating 
RAF/MeK/ERK signaling.189 This phenomenon, which has 
been attributed to v-raf murine sarcoma viral oncogene homo-
log C (CRAF) activation, is evident clinically in the develop-
ment of KRAS-mutant cutaneous squamous cell carcinomas in 
melanoma patients treated with BRAF inhibitors.190,191
A number of recent and ongoing clinical trials have 
focused on the pI3K/AKT/mTOR signaling cascade. 
Specific agents under investigation in KRAS-mutant NSCLC 
include the mTOR inhibitor ridaforolimus (IpI-504; Infinity 
pharmaceuticals, Cambridge, MA) (NCT00818675), the 
mTOR inhibitor everolimus in combination with the HSp90 
inhibitor retaspimycin (NCT01427946), everolimus in com-
bination with trametinib (NCT00955773), and the dual pI3K-
mTOR inhibitor BEZ235 (Novartis) in combination with 
MEK162 (Novartis) (NCT01337765, NCT01363232).
The ras homolog family member A (RHOA)-focal adhe-
sion kinase (FAK) axis has emerged as a critical mediator of 
RAS signal transduction. In transgenic and orthotopic mouse 
models of KRAS-mutant lung adenocarcinoma, FAK inhibi-
tion resulted in inhibition of tumor growth and prolongation of 
survival,192 leading to an ongoing multicenter phase II trial of 
the FAK inhibitor defactenib (VS-6063; Verastem, Needham, 
MA) in previously treated advanced KRAS-mutant NSCLC 
(NCT01951690).
In a randomized phase II clinical of erlotinib ± the 
c-MET inhibitor tivantinib (ARQ-197; ArQule, Woburn, MA), 
an exploratory analysis revealed that the small cohort with 
KRAS mutations achieved a pFS HR of 0.18 (95% CI, 0.05–
0.70).193 This benefit was hypothesized to be related to a puta-
tive feedback loop through which EGFR acts as a downstream 
mediator of KRAS signaling, interactions between hepatocyte 
growth factor (HGF) (the MET ligand) and KRAS, or non–
MET-mediated pathways. A subsequent randomized phase 
II clinical trial of erlotinib-positive ARQ-197 versus single-
agent chemotherapy in previously treated advanced KRAS-
mutant NSCLC (NCT0139578) has completed accrual.
Synthetic Lethality
With synthetic lethality, KRAS-mutant cancer cells are 
selectively killed by means of inhibition of a second protein. In 
KRAS-mutant cell lines, RNAi-based synthetic lethal screens 
have identified several potential targets. A number of these, 
including cyclin-dependent kinase 4 (CDK4), STK33, TBK1, 
and polo-like kinase 1 (pLK1), encode protein kinases and 
may therefore be amenable to small molecule inhibition.194
NSCLC WITH PI3K PATHWAY ALTERATIONS
pI3K signaling plays important roles in metabolism, 
growth, survival, and motility. The class IA pI3Ks are most 
clearly associated with human cancer and are activated by 
growth factor stimulation through RTKs. Class IA pI3Ks are 
composed of a regulatory subunit and catalytic subunit. The 
regulatory subunit, p85, is encoded by pIK3R1, pIK3R2, and 
pIK3R3, whereas the catalytic subunit has three isoforms such 
as p110α, p110β, and p110δ encoded by pIK3CA, pIK3CB, 
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and pIK3D, respectively. Binding of p85 to phosphotyrosine 
residues on RTKs releases the inhibition of p110 by p85 and 
causes localization of pI3K to the plasma membrane, where 
it can phosphorylate phosphatidylinositol 4,5-bisphosphate 
to produce phosphatidylinositol 3,4,5 trisphosphate (pIp3), 
which in turn propagates intracellular signaling by means of 
AKT and pyruvate dehydrogenase lipoamide kinase isozyme 1 
(pDK1) and other pIp3-dependent signaling pathways. pTEN 
dephosphorylates pIp3 to phosphatidylinositol 4,5-bispho-
sphate and thus inhibiting pI3K-dependent signaling and 
acting as a tumor suppressor. pI3K can also be activated by 
RAS or by G-protein–coupled receptors which bind directly 
to the catalytic subunit. pI3K–AKT signaling regulates mul-
tiple downstream pathways including the bcl2 family mem-
bers, forkhead transcription factors, MDM2/p53, mTORC1/2, 
and nuclear factor kappa-light-chain-enhancer of activated B 
cells (NFKB) pathways, to promote cell survival and inhibit 
apoptosis.195–197
Genetic Alterations in PI3K Pathway
Genetic alterations of elements in the pI3K pathway 
have been described in lung cancer and other tumor types. 
pIK3CA encodes the gene for the p110α isoform of the cata-
lytic subunit ofpI3K. Both copy-number gains and mutations 
in pIK3CA have been identified in lung cancer. pIK3CA 
copy-number gains occur in approximately 20% of lung can-
cers, with higher frequency in squamous cell carcinomas.198–200 
Somatic mutations in pIK3CA have also been described and 
promote the activation of the pI3K signaling pathway.201 
Mutations in pIK3CA are clustered in two hotspot regions in 
exons 9 and 20 encoding the helical and kinase domains of 
the protein, respectively. These mutations lead to increased 
lipid kinase activity and constitutive pI3K–AKT signaling.201 
The mechanism of action is different based on mutation type; 
for example, the helical domain mutants E545K and E542K 
interfere with the inhibitory interaction between the regulatory 
subunit p85 and the catalytic unit p110α, whereas the kinase 
domain mutant H1047R is located near the activation loop and 
leads to constitutive signaling through the kinase.195 pIK3CA 
mutations have been reported in 1% to 5% of NSCLC cell lines 
and tumors.198,202 Kawano et al.202 found pIK3CA mutations in 
6.5% of lung squamous cell carcinomas and less often in lung 
adenocarcinomas (1.5%). pIK3CA mutations often do not 
exist in isolation, and coexistence with other mutations, such 
as KRAS, NRAS, BRAF, and EGFR, is common.203–205 A study 
among patients with lung adenocarcinoma in the United States 
reported 70% of cases with pIK3CA mutation had a coexisting 
driver mutation, with the most frequent partner being KRAS.205
The tumor suppressor gene pTEN encodes a lipid phos-
phatase that negatively regulates the pI3K/AKT pathway, 
and loss of pTEN leads to constitutive pI3K–AKT signal-
ing. Somatic pTEN deletions and mutations, and inactivation 
of pTEN by epigenetic mechanisms such as methylation or 
microRNA silencing, are seen in multiple cancers.206 pTEN 
mutations occur in approximately 5% of lung cancers and are 
significantly associated with squamous cell rather than adeno-
carcinoma histology (10.2% versus 1.7%).207 Reduction or 
loss of pTEN expression has been reported in up to 70% of 
NSCLC, both adenocarcinoma and squamous cell.208
Other mutations in elements of the pI3K pathway have 
also been reported. For example, a somatic mutation in AKT, 
E17K, constitutively activates the protein kinase.209 The AKT1 
E17K mutation was found in 5.5% (two of 36) squamous cell 
lung cancers, but not (zero of 53) in lung adenocarcinoma.210 
pIK3R1 mutations causing truncations or in-frame deletions 
have also been reported and are thought to relieve the inhibi-
tory effect of p85 on p110, thereby activating pI3K signaling.
Drug Development
There are multiple pI3K inhibitors in development, 
with specificity ranging from pan-pI3K inhibitors to isoform-
selective pI3K inhibitors and dual pI3K/MTOR inhibitors. 
As a class, common adverse events have been hyperglycemia 
(which is thought to be due to the role pI3K plays in the insu-
lin signaling pathway), maculopapular rash, and gastrointesti-
nal issues such as nausea, vomiting, dyspepsia, diarrhea, and 
stomatitis. In addition to the phase I studies of pI3K inhibitors 
that enrolled all tumor types, there are many ongoing trials 
with a focus on lung cancer, both as monotherapy and in com-
bination with other agents. There have been multiple phase 
I/Ib studies combining various pI3K inhibitors with MEK 
inhibitors which have enrolled expansion cohorts of patients 
with KRAS-mutated lung cancer; efficacy results from these 
trials are awaited. In nonmolecularly selected lung cancer 
populations, currently ongoing trials include GDC0941 in 
combination with carboplatin, paclitaxel, with or without bev-
acizumab, and BKM120 in combination with docetaxel or car-
boplatin/pemetrexed. BKM120 is also being tested singly and 
in combination with EGFR inhibitors in molecularly selected 
cohorts. GDC0032 is also being tested in combination with 
chemotherapy agents including docetaxel and paclitaxel.
preclinical data have suggested that cancers harboring 
activating mutations in pIK3CA may be among the most sen-
sitive to single-agent pI3K pathway inhibitors.195 In general, 
the clinically observed activity of pI3K inhibitors as mono-
therapy has been modest, and it is not entirely clear how well 
molecular alterations in pI3K pathway correlate with antitu-
mor effect.211 In one institution’s cumulative phase I experi-
ence, patients with pI3K mutations who were enrolled in 
phase I trials with pI3K/AKT/MTOR inhibitors had a higher 
pR rate than wild-type pI3K patients on their best phase I 
therapy.203 However, the RRs reported (18% for pI3K-mutated 
patients versus 8% for wild-type, with H1047R mutations 
faring best with a 38% pR rate),203 still leave much room for 
improvement and are not comparable with the RRs achieved 
with the landmark-targeted therapies used for EGFR or ALK 
inhibition. The frequent coexistence of other driver mutations 
may mean that single-agent pI3K inhibition may not be suffi-
cient if the coexisting driver is not effectively targeted as well. 
In addition, signaling feedback loops may be activated that 
promote growth by means of alternative pathways; for exam-
ple, mTORC1 inhibition leads to the activation of pI3K path-
way through a feedback loop, limiting single-agent mTORC1 
efficacy.195 Finally, it remains unclear whether the drugs in 
development thus far are achieving an adequate therapeutic 
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window; observed pathway inhibition in various trials has 
ranged from 30% to 90%, and it is possible that at the dosing 
levels achieved there may not be sufficient pathway inhibition 
to have an antitumor effect.211
MET-POSITIVE NSCLC
The MET/HGF pathway has been identified as a poten-
tial therapeutic target in multiple solid tumors, including 
NSCLC.212–214 The MET gene on chromosome 7q21-31 encodes 
the HGF receptor (HGFR), which is a single-chain heterodimer 
consisting of a 50-kDa extracellular α-chain and a 140-kDa 
transmembrane β-chain. Binding of the HGF ligand leads to 
dimerization of the receptor and phosphorylation of the intra-
cellular TK domain.215 This results in activation of downstream 
signaling pathways, such as pI3K–AKT and RAS–MAp–
kinase, which are involved in cell survival and apoptosis, cell 
proliferation and differentiation, cytoskeletal function, angio-
genesis, and other cellular functions.216,217 There is also crosstalk 
between MET and other RTKs, including EGFR/ERBB family 
of receptors, which can result in HGF-independent activation 
of the MET pathway.212,213,218 Ligand-mediated MET is tightly 
controlled through recruitment of Casitas B-lineage Lymphoma 
(CBL) (E3 ubiquitin ligase), which binds to the regulatory site 
of the juxtamembrane domain of HGFR and leads to ubiqui-
nation of HGFR into clathrin-coated vesicles, with ultimate 
degradation.219
Aberrant signaling of the MET pathway can occur 
through overexpression of HGF or HGFR, decreased degra-
dation of HGFR, MET amplification, or MET mutations.212,213 
In NSCLC, the most common mechanism for aberrant MET 
signaling is overexpression of HGF and HGFR. HGFR over-
expression is associated with poor prognosis and has been 
reported to occur in up to 61% of NSCLC,220,221 including 25% 
to 67% of patients with adenocarcinoma of the lung.220 The 
prevalence of de novo MET amplification is low (≤5%)11 to 15 
but is also associated with poor prognosis.221 Importantly, MET 
amplification has been identified as a mechanism for acquired 
resistance to EGFR TK inhibition in a subset (5%–20%) of 
patients with activating EGFR mutations through ERBB3-
dependent activation of the pI3K pathway.85,222,223 It is also 
seen that amplification can be de novo without resistance. Both 
somatic and germline MET mutations have been identified in 
multiple solid tumors.212 In NSCLC, mutations in the extracel-
lular semaphorin domain (exon 2) and intracellular juxtamem-
brane domain (exon 14–15, including exon skipping), which 
can affect ligand binding and receptor downregulation, respec-
tively, have been described.220,224,225 In a recently reported series 
that included 106 patients with NSCLC who underwent MET 
mutational analysis, approximately 4% were found to be MET-
mutation positive (exon 14–15).226
Both in vitro and in vivo preclinical models have estab-
lished the utility of MET pathway inhibitors to suppress HGF-
dependent and HGF-independent MET phosphorylation and 
activation of downstream pathways, resulting in inhibition of 
both tumor growth and metastasis.212 Dual inhibition of EGFR 
and MET in in vivo tumor xenograft models has been shown 
to be additive and potentially synergistic in NSCLC, includ-
ing in tumors with acquired resistance to EGFR TKIs.227,228 
Recently we have also shown that MET can synergize with its 
family member Recepteur d’Origine Nantais (RON).229 MET 
targeting strategies have included inhibitors of the HGF-HGFR 
binding, including HGF antagonists, HGFR inhibitors, and 
decoy MET, as well as small molecule inhibitors of the intra-
cellular TK domain.212–214 The preclinical experience has led to 
clinical testing of both single-agent and combination strategies 
to inhibit the MET pathway in NSCLC.
Monoclonal Antibodies 
Targeting HGF and HGFR
AMG 102 (rilotumumab) and AV 299 (ficlatuzumab) 
are monoclonal antibodies targeting HGF. Rilotumumab is a 
fully humanized monoclonal antibody that has been shown to 
improve the activity of chemotherapy in preclinical and clinical 
testing in tumors that overexpress MET.230,231 In phase I testing 
as a single agent, rilotumumab was well tolerated with most 
common treatment-related adverse events including fatigue 
(13%), constipation (8%), and nausea (8%).232 A phase I/II trial 
is currently ongoing evaluating rilotumumab with erlotinib 
in previously treated patients with NSCLC (NCT01233687). 
Ficlatuzumab is a human anti-HGF IgG1 monoclonal anti-
body.233 In phase I testing, ficlatuzumab was well tolerated with 
no additional safety signals identified when combined with an 
EGFR TKI.234 In a randomized phase II trial comparing gefi-
tinib with gefitinib plus ficlatuzumab in never or former light 
smokers with previously untreated adenocarcinoma of the lung, 
there was no significant difference in RR (40% versus 43%) or 
pFS (4.7 versus 5.6 months) between the two groups (gefitinib 
versus gefitinib + ficlatuzumab, respectively).235 Interestingly, 
in subgroup analysis, patients with activating mutations in the 
EGFR gene and low MET expression appeared to gain the most 
benefit from the combination (overall RR 70% versus 44% and 
median pFS 11.0 versus 5.5 months).235
MetMab (Onartuzumab) and LY-2875358 are monoclo-
nal antibodies directed against the MET receptor. MetMab is 
a humanized, monovalent monoclonal antibody that inhibits 
HGF/MET binding without inducing MET dimerization.236,237 
In contrast, LY-2875358 is a bivalent MET receptor antibody 
that can inhibit both HGF-mediated signaling by binding to 
the MET receptor and HGF-independent activation of the 
MET pathway by inducing internalization and degradation of 
MET.238 LY-2875358 has confirmed antitumor activity in in 
vivo and in vitro models.239,240 A phase I trial as a single agent 
and in combination with erlotinib has been reported with no 
dose-limiting toxicities, serious, or grade III adverse events.241 
Currently, LY-2875358 is being evaluated in two phase II trials, 
including a randomized phase II with erlotinib versus erlotinib 
alone in patients with advanced-stage EGFR-mutated NSCLC 
(NCT01897480), as well as a single-agent or combined with 
erlotinib in patients with MET diagnostic positive NSCLC 
that has progressed on erlotinib.
Onartuzumab has been evaluated in a randomized phase 
II trial in patients with recurrent NSCLC in combination with 
erlotinib versus erlotinib alone.242 There was no significant dif-
ference in the primary pFS end point in the intention-to-treat 
population (HR, 1.09; p = 0.69). However, in the prespecified 
MET-positive population (defined by a score of 2 to 3+ by IHC 
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[≥50% of cells with strong or moderate or higher staining using 
CONFIRM Sp44 anti-MET monoclonal antibody]) the combi-
nation arm was associated with improved pFS (HR, 0.53; p = 
0.04) and OS (HR, 0.37; p = 0.002).242 A phase III trial evalu-
ating this combination versus erlotinib alone in MET-positive 
patients with advanced-stage NSCLC who have received prior 
chemotherapy is ongoing (MetLung; NCT01456325).
MET TKIs
Targeting the MET TK has the potential to inhibit both 
HGF-dependent and HGF-independent signaling through the 
MET pathway. There are a number of MET TKIs currently 
undergoing testing in early-phase clinical trials.213 Although 
crizotinib is FDA-approved for ALK-translocated NSCLC, 
it also has in vitro activity against MET. In a case report, a 
patient with advanced-stage MET-amplified (MET/CEp7 
ratio >5.0) and ALK-negative NSCLC was reported achieved 
a rapid and durable response after treatment with crizotinib.243
Cabozantinib (XL184) is an ATp-competitive inhibitor 
of MET, VEGFR, and RET with documented phase II activity 
in an unselected pretreated cohort of 60 patients with advanced 
NSCLC (overall RR 10%; disease control rate 40%).244 The com-
bination of cabozantinib with erlotinib was also shown to be active 
in a phase IB trial of patients with previously treated NSCLC, the 
majority of who had received prior erlotinib.245 In this trial, two of 
53 patients had confirmed MET gene copy-number gain and both 
achieved tumor shrinkage with the combination.
On the basis of a promising randomized phase II trial, the 
phase III MARQUEE trial was initiated to test the combination 
of tivantinib (ARQ 197), a non–ATp-competitive TKI of MET, 
with erlotinib in previously treated patients with advanced 
NSCLC. This trial was stopped at the interim analysis because 
the primary OS end point was not met. Recent in vitro stud-
ies demonstrated that tivantinib is a cytotoxic drug affecting 
microtubule dynamics with activity in cell lines independent 
of MET activity. It is feasible that tivantinib is a weak MET 
inhibitor and has differential activity in different tumors.246–248
FGFR-POSITIVE NSCLC
Dysregulation of FGFR family signaling has been 
described in a broad range of cancers, including lung, breast, 
prostate, myeloma, sarcoma, bladder, and endometrial can-
cers, among others.249–254 Amplification, translocation, and 
point mutations involving FGFR family members have all 
been described across the various tumor types, and each of 
these genetic alterations occurs in lung cancer.
The FGF/FGFR family consists of 18 FGF ligands which 
bind to four homologous FGFR RTKs (FGFR 1, 2, 3, and 4). 
A typical FGFR is composed of an extracellular domain with 
three IG-like domains, a transmembrane domain, and a split 
TK domain. Binding of FGF ligand to FGFRs induces recep-
tor dimerization, which leads to transphosphorylation of a 
tyrosine in the activation loop of the TK domain. Activation 
leads to downstream signaling via the pI3K/AKT and RAS/
MApK pathways which are central to growth, survival migra-
tion, and angiogenesis.249–254
Amplification
Amplification at 8p12 was observed in multiple stud-
ies of squamous cell lung cancer,16,18,255 and FGFR1 has been 
identified as a potential candidate gene in this region. Weiss 
et al.18 identified focal amplifications in FGFR1 correspond-
ing to the 8p12 amplification in a study of 155 primary squa-
mous cell lung cancer specimens, which they validated in an 
independent set of 153 squamous cell lung cancers. Similarly, 
Dutt et al.16 reported FGFR1 amplification in approximately 
20% of squamous cell lung cancers and rarely in adenocarci-
noma (3%). Inhibition of FGFR1 in amplified cell lines and 
in mouse models with FGFR1-amplified engrafted tumors 
showed growth inhibition and induced apoptosis.
It remains unclear whether FGFR1 amplification is a 
prognostic marker in lung cancer. Weiss et al. reported that 
FGFR1 amplification (copy number >9 by FISH) had a trend 
toward worse survival compared with patients who lacked 
FGFR1 amplification (copy number = 2 by FISH). Multiple 
studies have investigated the potential prognostic role of 
FGFR1 among patients with squamous cell lung cancer; 
some have reported no effect of FGFR1 amplification on 
survival,256,257 whereas others have reported inferior survival 
with FGFR1 amplification,18,258,259 and one reported potential 
improved survival.260 Comparison across studies is limited by 
the heterogeneity in definitions of amplification, and there is 
not yet a defined standard in the field.
Fusions
In addition to FGFR1 amplification, fusions involving 
FGFR3 have recently been reported in lung cancer.20–22 Fusions 
involving FGFR3 have been reported in other cancers includ-
ing glioblastoma and bladder cancer.261 Kim et al.20 performed 
whole exome sequencing of lung squamous cell cancers from 
Korean patients and identified an in-frame fusion of FGFR3 
with TACC3. Overall two of 148 Korean lung squamous cell 
cancers had this fusion; probing the TCGA data set revealed 
another four of 178 samples with the FGFR3-TACC3 fusion.20 
Majewski et al.21 used kinome-centered RNA sequencing on 
95 lung cancer samples and identified two squamous cell lung 
cancers with FGFR3-TACC3 fusions. FGFR3 fusions resulted 
in overexpression of fusion proteins and enhanced prolif-
eration of cells and activation of downstream MApK–ERK 
pathways.22 Studies in bladder cancer and glioblastoma have 
invoked various hypotheses for the transforming capacity of 
FGFR3-TACC3, including constitutive activation and signaling 
via downstream MApK pathway,262 localization to the mitotic 
spindle, causing chromosomal missegregation and aneu-
ploidy,263 or loss of a 3'UTR miR-99a binding site resulting in 
enhanced expression of the fusion transcripts.264 Importantly, 
multiple studies have shown sensitivity of FGFR3 fusion cell 
lines and xenograft models to FGFR inhibitors.22,262,263
Point Mutations
point mutations in FGFR have also been identified as 
potentially oncogenic, in particular mutations in FGFR2 and 
FGFR3. Analysis of whole exome data from TCGA identi-
fied five FGFR2 and six FGFR3 mutations from 178 tumor/
normal pairs.265 The observed mutations fell within both the 
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extracellular and kinase domains of FGFR2 and FGFR3 and 
included previously identified mutations in other tumor types 
and novel mutations. Some of these mutations were transform-
ing in anchorage-independent growth assays and xenograft 
assays. In particular, extracellular domain mutations W290C 
and S320C in FGFR2 and S249C in FGFR3, as well as kinase 
domain mutations K660E and K660N in FGFR2, significantly 
increased colony formation in anchorage-independent growth 
assays as compared with wild type (in contrast, FGFR2 E471Q 
and T787K, and FGFR3 S435C and K717M were not trans-
forming). The transforming ability of the specific FGFR2 and 
FGFR3 mutations was inhibited by multiple of the small mol-
ecule FGFR inhibitors currently in clinical development.265
Drugs
Many FGFR inhibitors are in development and have mul-
titargeted activity and inhibit other kinases in addition to FGFR, 
most notably VEGFR, pDGFR, FLT3, RET, KIT, among oth-
ers.261 Selective FGFR inhibitors are also in development and 
preliminary results have been reported for some of these trials. 
A phase I study of BGJ398 is enrolling patients with advanced 
solid malignancies with FGFR1 or FGFR2 amplification or 
FGFR3 mutation. A preliminary report in 2012 reported 26 
patients having been treated, including 10 with FGFR1 amplified 
breast cancer and three with FGFR1-amplified lung squamous 
cell cancer. The most frequent adverse events included diarrhea, 
fatigue, nausea, and hyperphosphatemia, with dose-limiting 
toxicities of grade 3 elevations in transaminases and grade 2 
corneal events. Hyperphosphatemia may be a class effect due to 
blockade of FGF23 signaling but seems controllable with phos-
phate binders and diuretics. One patient with lung cancer and 
FGFR1 amplification (FGFR1/CEp8 ratio of 2.6 by FISH) had 
a confirmed pR.266 A phase I study of AZD4547, with selection 
for FGFR1 and FGFR2 amplification in the later phases of the 
study has completed accrual, and final results are pending. In 
a preliminary report, dose-limiting toxicities included hyper-
phosphatemia, renal failure, mucositis, and increased transami-
nases. A preliminary report in 2013 reported on 21 patients with 
FGFR1- or FGFR2-amplified tumors on study. One patient 
with FGFR1-amplified lung squamous cancer had a pR,267 with 
another patient with FGFR1-amplified lung squamous cancer 
having a prolonged period of SD. Although some are selecting 
for specific FGFR family alterations, others are more inclusive 
and enroll specific tumor types without molecular character-
ization required a priori. Class specific effects of the selective 
FGFR inhibitors are thought to include hyperphosphatemia and 
tissue calcification due to FGF23 blockade; although this is a 
class-specific adverse event, increases in FGF23, phosphate, 
and vitamin D levels may also serve as potential biomarkers 
for effective FGFR inhibition.282 Most of these studies are with 
single agents although a few are testing in combination with 
various chemotherapy regimens.
MITOTIC/CYCLIN INHIBITORS  
IN LUNG CANCER
Disrupting cell division has been a cornerstone of can-
cer drug development. Mitotic inhibitors are among the most 
widely developed agents in oncology and have been used in 
lung cancer treatment for more than three decades. These agents 
bind tubulin and prevent polymerization to microtubules, 
hence, preventing cell division. Multiple mitotic inhibitors 
have been developed and many are still standard therapies in 
lung cancer treatment including paclitaxel, docetaxel, vinorel-
bine, and etoposide. These agents are routinely combined in 
platinum regimens in the adjuvant, locally advanced, and meta-
static NSCLC; and platinum/etoposide remains the established 
treatment for limited- and extensive-stage SCLC.
More recent advances in targeting cell cycling have come 
with the development of cell cycle checkpoint inhibitors. Cell 
cycle check points are important in maintaining genomic stabil-
ity and preventing cancer development in normal cells (Fig. 5).268 
These checkpoints help in cellular surveillance of DNA damage 
by causing cycle arrest and permitting DNA repair. However, 
these checkpoints also protect cancer cells from the effects of 
DNA-damaging agents such as cisplatin/carboplatin and gem-
citabine and from the effects of radiation. CDKs are key regu-
lators of sequential progression through the G1, S, G2, and M 
phases of the cell cycle. Checkpoint kinase inhibitors disrupt 
the ability of cancer cell to repair this damage and have recently 
shown promising activity as single agents in selected patient 
populations and in combination with DNA-damaging therapies 
in broader tumor settings.269,270 Many of these novel agents are 
being developed in lung cancer treatment.
LY2606368
LY2606368 is an oral small molecule selective ATp-
competitive inhibitor of the checkpoint kinase 1 (CHK1), and 
to a lesser extent CHK2. CHK1 and 2 regulate DNA damage 
response by inhibiting CDK1 preventing the entry into mito-
sis.271 This leads to cell cycle arrest, DNA repair, and apoptosis 
FIGURE 5.  Mitotic/cyclin inhibitors. NHEJ, non-homologous 
end joining; HR, homologous recombination.
S50 Copyright © 2014 by the International Association for the Study of Lung Cancer
Morgensztern et al. Journal of Thoracic Oncology ®  •  Volume 10, Number 1, Supplement 1, January 2015
of damaged cells.272 LY2606368 has been shown to potentiate 
DNA-damaging agents and has potent antitumor activity as a 
single agent in preclinical studies.273 LY2606368 is currently 
in a phase I study in patients with advanced refractory squa-
mous NSCLC, head and neck cancer, and anal cancer (N = 
150; NCT01115790).
Palbociclib (PD-0332991)
palbociclib (pfizer) is an oral CDK4/6 inhibitor, inhibit-
ing retinoblastoma (Rb) protein phosphorylation in early G1 
and disrupting cell cycle progression to S phase. palbociclib 
has recently shown remarkable activity in a randomized phase II 
trial in patients with advanced hormone-positive breast cancer.274 
One hundred sixty-five women were randomized 1:1 to 2.5 mg 
of letrozole orally daily ± 125 mg palbociclib daily for 3 weeks 
followed by 1 week off. The primary end point was investigator-
assessed pFS. palbociclib/letrozole was associated with a signif-
icant improvement in pFS compared with letrozole alone (20.2 
versus 10.2 months; HR, 0.488; 95% CI, 0.32–0.75; one-sided p 
= 0.0004). The most common toxicities in the palbociclib/letro-
zole arm were neutropenia, leukopenia, fatigue, and anemia. 
palbociclib is in planned investigation in CDK4/6-amplified 
recurrent squamous lung cancer as part of the National Cancer 
Institute–sponsored biomarker driven “Master” protocol.
LY2835219
LY2835219 (Eli Lilly) is an oral selective ATp-
competitive inhibitor of CDK4/6 which has entered into phase 
I study in NSCLC (NCT02079636). Ninety-nine patients will 
be enrolled across multiple cohorts including combinations 
with pemetrexed (nonsquamous only), gemcitabine, ramici-
rumab, and trametinib. Development in other tumors includ-
ing breast cancer, colorectal cancer, melanoma, glioblastoma 
multiforme, and mantle cell lymphoma is ongoing.
AZD1775
Tp53 mutations are the most common genomic 
alterations in lung cancer, occurring in an estimated 51% 
of squamous lung cancers and 34% of adenocarcinomas 
(Catalogue of Somatic Mutations in Cancer [COSMIC]). 
These mutations render the G1 checkpoint defective, making 
these cancers more dependent on the S/G(2) cell cycle check-
point for repair and resistant to DNA-damaging agents. This 
resistance can be overcome in the presence of S/G(2) inhibi-
tors.271 The WEE1 kinase coordinates cell cycle progression 
and DNA damage checkpoints. AZD1775 (Astra-Zeneca) is 
an oral ATp-competitive inhibitor of WEE1 (concentration 
that inhibits 50% 5 nM; EC50 80 nM versus pCDK1Y15).275 
WEE1 inhibition leads to unregulated CDK1 (and 2) activity, 
overriding S/G2 checkpoints leading to mitotic catastrophe 
and cell death in DNA damaged cells. This activity may be 
most pronounced in p53-mutated (G1-deficient) cells in com-
bination with platinum-based and gemcitabine-based regi-
mens. A phase I trial of AZD1775 + cisplatin, + carboplatin, 
and +gemcitabine in more than 180 patients with refractory 
solid tumors has recently been completed; and early activity 
and safety have been reported in combination with carbopla-
tin/paclitaxel in patients with p53-mutated platinum-sensitive 
recurrent ovarian cancer.276 AZD1775 has entered into trials in 
p53-mutated lung cancer: a first-line randomized phase trial of 
carboplatin/pemetrexed ± AZD1775 in patients with nonsqua-
mous NSCLC (NCT02087241); and a second-line random-
ized phase II trial of docetaxel ± AZD1775 in patients with 
nonsquamous and squamous histologies (NCT02087176). 
Trials are also ongoing in p53-mutated platinum-sensitive and 
platinum-resistant recurrent ovarian cancer.
Volasertib (PLK-1 ONO01910)
pLK1 is important for cellular recovery from G2/M 
arrest due to DNA damage. Overexpression of pLK1 leads to 
chromosomal instability and is seen in many tumors including 
NSCLC.277 Volasertib is an i pLK1 inhibitor in development 
in NSCLC. Recent data were presented from a study of 131 
patients with recurrent nonsquamous NSCLC randomized 1:1:1 
to volasertib 300 mg/m2, volasertib 300 mg/m2 and pemetrexed 
500 mg/m2, or pemetrexed alone IV day 1 every 3 weeks.278 The 
median pFSs (primary end point) for these cohorts were: 1.4, 
FIGURE 6.  PARP inhibition: Mechanism of action (reproduced from Oncology Live, 2013, permission requested). BER, base 
excision repair; NAD, nicotinamide adenine dinucleotide; PARP, Poly(ADP-ribose) polymerase.
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3.3, and 5.3 months, respectively. The ORRs were 8.1%, 21.3%, 
and 10.6%, respectively. Grade 3/4 toxicity was primarily lim-
ited to fatigue (all arms) and neutropenia (volasertib/peme-
trexed, 11%). Development of volasertib is ongoing in acute 
myeloid leukemia and urothelial cancer.
Alisertib (MLN8237)
The aurora kinases play important roles in mitosis. Aurora 
kinase A promotes mitosis through activation of CDK1, and its 
overexpression has been linked to taxane resistance. Aurora 
kinase B is linked to cytokinesis, and its inhibition leads to dys-
functional chromosomal alignment and segregation. Several 
aurora kinase inhibitors (A and B) are in development.
Alisertib (Millennium) is an oral aurora kinase A inhibi-
tor. A phase I/II trial of alisertib in patients with refractory 
SCLC, NSCLC, breast cancer, head and neck cancer, and 
gastroesophageal cancer was recently presented.279 patients 
received the recommended phase II dose of 50 mg orally twice 
a day for 1 week every 3 weeks. The ORR in 23 patients with 
NSCLC was 4% with a median pFS of 3.1 months. However, 
in the SCLC (n = 47) cohort, the ORR was 21% (including 3 
patients [ORR 27%] with refractory relapsed disease) with a 
pFS of 2.8 months. Grade 3/4 toxicities (all patients) included 
neutropenia (38%), anemia (10%), stomatitis (8%), and throm-
bocytopenia (6%). A randomized phase II study of paclitaxel 
± alisertib in patients with relapsed SCLC (NCT02038647), 
and a trial of alisertib and erlotinib in patients with EGFR-WT 
NSCLC (NCT01471964) are in progress. Several other A and 
B, and pan-aurora, kinase inhibitors are in early development 
in solid and hematologic cancers.
POLY (ADENOSINE DIPHOSPHATE-RIBOSE) 
POLYMERASE INHIBITORS IN LUNG CANCER
poly (adenosine diphosphate [ADp]-ribose) poly-
merase (pARp) includes a family of 17 proteins that play 
important roles in DNA repair.280 In addition to its func-
tion in DNA repair, pARp proteins also play major roles in 
a number of other cellular processes such as transcription, 
epigenetic regulation, mitosis, and inflammation, which have 
all been recognized in recent years. pARp 1 and 2 are consid-
ered to be highly relevant for DNA repair. After single-strand 
DNA damage, pARp is recruited as the first step of the repair 
process (Fig. 6).281 Subsequently, multiple ADp–ribose units 
are added to the complex in a NAD-dependent manner. This 
confers a net negative charge that induces conformational 
changes and attracts a number of key repair proteins such 
as DNA ligase III, X-ray cross-complementing gene 1, etc., 
which ultimately work to repair the DNA damage. In situa-
tions of catastrophic DNA damage, massive recruitment of 
pARp leads to depletion of NAD, resulting in necrotic cell 
death. Thus the extent of pARp activation could be the deter-
minant of successful DNA repair or cell death. Unrepaired 
single-strand damage leads to double-strand DNA damage 
that is repaired by the homologous recombination repair 
pathway. In subjects with breast cancer, early onset (BRCA) 
1 or 2 mutations, the homologous recombination pathway is 
deficient and there is an overwhelming reliance on pARp for 
DNA repair.282
PARP Inhibition
pARp inhibition was initially studied in cancer in com-
bination with agents that induce DNA repair such as plati-
num compounds, alkylating agents, and ionizing radiation.283 
Suppression of DNA repair with pARp inhibitors in conjunc-
tion with these agents results in enhanced anticancer activ-
ity in several preclinical models. In patients with deficient 
homologous recombination pathway, pARp inhibition results 
in robust anticancer activity due to the reliance of these cells 
on pARp for DNA repair.282 This effect, referred to as “syn-
thetic lethality,” has formed the basis for the evaluation of 
pARp inhibitors as monotherapy in breast and ovarian can-
cer patients who have BRCA 1 or 2 mutations. In lung can-
cer, BRCA mutations are rare and hence pARp inhibitors are 
unlikely to be effective as monotherapy. A small subset of 
lung cancer patients are known to have “functional” BRCA 
deficiency and could be candidates for the monotherapy 
approach even though this has not been tested in clinical tri-
als. Approximately 10% of NSCLCs harbor a mutation in 
ataxia telangiectasia mutated (ATM) gene, a condition with 
known deficiency in homologous recombination.27 Another 
mechanism referred to as “pARp trapping” has recently been 
described to account for the anticancer effects of pARp inhibi-
tion.284 Retention of the pARp inhibitor–DNA complex con-
fers cytotoxicity to cells and the extent of pARp trapping is 
variable among the presently available pARp inhibitors, con-
tributing to potential differences in efficacy of these agents 
based on this effect.
A number of novel pARp inhibitors are presently in clin-
ical development for the treatment of cancer. Iniparib, which 
was initially considered to be a pARp inhibitor, had been tested 
in phase III studies in breast cancer and squamous cell lung 
cancer in combination with platinum-based chemotherapy.285 
These studies failed to demonstrate survival benefit, and by 
then, it was also clear that the mechanism of action of inparib 
was not related to pARp inhibition. Recently, the use of olapa-
rib, a potent small molecule inhibitor of pARp, as maintenance 
therapy in platinum-sensitive ovarian cancer was associated 
with a significant improvement in pFS compared with pla-
cebo (8.4 versus 4.8 m, p < 0.001).286 In another phase II study, 
olaparib demonstrated an RR of approximately 40% in ovarian 
cancer patients with BRCA mutation.287 Veliparib, a small mol-
ecule pARp inhibitor, improved the pathological complete RR 
for patients with breast cancer in the neo-adjuvant therapy set-
ting. From these lines of evidence, it is clear that pARp inhibi-
tors represent a novel approach for the treatment of cancer.
PARP Inhibitors under Development 
in Lung Cancer
Small-cell lung cancer
Increasing evidence suggests that pARp inhibition 
might be a novel strategy for the treatment of SCLC.288 
Objective responses have been reported with BMN-673, a 
highly potent pARp inhibitor when given as monotherapy to 
patients with SCLC that had progressed on standard chemo-
therapy. Biological rationale for the sensitivity of SCLC might 
be due to the higher pARp 1 expression and other DNA repair 
proteins in SCLC tumor samples. On the basis of the synergy 
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between alkylating agents and pARp inhibitors, a phase II 
study is presently evaluating the combination of temozolamide 
in combination with veliparib, a pARp inhibitor, for patients 
with relapsed/refractory SCLC (NCT01638546). The Eastern 
Cooperative Oncology Group is conducting a randomized 
phase II study of cisplatin and etoposide with either velipa-
rib or placebo for first-line therapy of patients with extensive 
stage SCLC (EA2511) (NCT01642251). Veliparib is given at 
a dose of 100 mg twice-daily on days 1 to 7 of each treatment 
cycle to synchronize with the administration of cisplatin (day 
1) and etoposide (days 1–3). This ongoing study will enroll a 
total of 135 patients with the primary end point of comparing 
median pFS between the two arms.
Non–small-cell lung cancer
Because platinum-based chemotherapy is the standard 
treatment for majority of patients with NSCLC, the use of pARp 
inhibitors in combination with platinum compounds has been 
studied extensively in preclinical studies. A phase I study of 
carboplatin, paclitaxel, and veliparib in patients with advanced 
solid organ malignancies noticed good tolerability and promis-
ing activity in advanced NSCLC.289 Subsequently, a randomized 
phase II study of carboplatin and paclitaxel with either velipa-
rib or placebo for first-line therapy of advanced NSCLC was 
conducted. Accrual to this study has been completed and the 
results are awaited (NCT01560104). The same combination is 
presently being tested in conjunction with radiation therapy for 
patients with surgically unresectable, locally advanced NSCLC 
by the Southwest Oncology Group (NCT01386385).
Olaparib, another pARp inhibitor, is also under exten-
sive evaluation in NSCLC. A European study will adminis-
ter olaparib in combination with cisplatin and radiotherapy to 
patients with unresectable stage III NSCLC (NCT01562210). 
It is also being studied as maintenance therapy for advanced 
NSCLC following combination chemotherapy in a random-
ized study (NCT01788332). More recently, a phase Ib/II study 
has been initiated to evaluate the combination of olaparib with 
gefitinib in patients with advanced NSCLC that harbor an 
EGFR mutation (NCT01513174).
IMMUNE CHECKPOINT INHIBITORS
Lung cancer has not traditionally been viewed as an 
immune responsive tumor. Immune checkpoint inhibitors have 
recently demonstrated promising results in lung cancer patients. 
In particular inhibitors to cytotoxic T-lymphocyte-associated 
antigen 4 (CTLA-4) and pD-1 and pD-L1 have shown promise 
in early studies and are currently in clinical trials in both SCLC 
and NSCLC. This review provides an update on immune check-
point inhibitors currently in development in lung cancer patients.
Anti-CTLA-4 Inhibitors
Ipilimumab is a fully human IgG1 antibody to CTLA4 
that inhibits the binding of CTLA4 to its ligands (CD80 or B7-1 
and CD86 or B7-2). Inhibition augments T-cell activation and 
proliferation resulting in T-cell infiltration of tumor cells and 
tumor regression.290 It is approved by FDA for the treatment of 
melanoma.291 Ipilimumab was evaluated in a randomized phase 
II trial that compared six cycles of standard chemotherapy 
(carboplatin and paclitaxel) with two different schedules of 
ipilimumab in 204 patients with stage IV NSCLC.292 In the 
concurrent schedule ipilimumab was given with cycle 1 to 4 of 
chemotherapy followed by two doses of placebo, in the phased 
schedule placebo was given with the first two cycles of chemo-
therapy and ipilimumab was added with cycle 3 to 6. Eligible 
patients were given maintenance ipilimumab or placebo every 
12 weeks until progression. The primary end point was immune 
relate pFS (irpFS). This end point was chosen to better capture 
the unique pattern of response to immune therapy including 
regression of index lesions in the face of new lesions and initial 
progression followed by tumor stabilization or regression.293,294 
The phased arm demonstrated an improvement in irpFS com-
pared with chemotherapy (5.7 versus 4.6 months; HR, 0.72; p 
= 0.05), and OS (12.2 versus 8.3 months). The concurrent arm 
did not result in an improvement in irpFS (5.5 months; HR, 
0.81; p = 0.81) or OS (9.7 months). There was also a higher 
World Health Organization best overall RR in the phased arm 
compared with chemotherapy or concurrent (32%, 18%, and 
21%, respectively). Treatment-related adverse events were 
similar across treatment groups (concurrent, 41%; phased, 
39%; and control, 31%). However, grade 3/4 immune-related 
adverse events were higher in the concurrent (20%) and phased 
(15%) arms compared with the control (6%). Two treatment-
related deaths were reported including one in the concurrent 
arm due to septic shock secondary to epidermal necrolysis, and 
one death occurred in the control arm as a result of neutropenic 
sepsis. In a preplanned subset analysis patients with squamous 
cell carcinoma had a significantly improved irpFS (HR, 0.55; 
95% CI, 0.27–1.12) and OS (HR, 0.4; 95% CI, 0.22–1.03) 
when treated with the phased schedule. This was not observed 
in nonsquamous NSCLC patients or for any histology treated 
with the concurrent schedule. On the basis of these promising 
results, a randomized phase III trial is underway comparing 
standard chemotherapy with or without phased ipilimumab in 
patients with squamous cell NSCLC (NCT01285609).
The same trial enrolled 103 patients with extensive-stage 
SCLC and noted an improvement in ifpFS in patients treated 
with the phased ipilimumab schedule compared with chemo-
therapy alone (6.4 versus 5.3 months; HR, 0.64; p = 0.03) with 
a nonsignificant trend toward improvement in RR (57% versus 
49%) and OS (12.9 versus 9.9 months).295 This was not seen 
in the concurrent treatment arm (pFS 3.9 months, RR 30% 
and OS 9.1 months). Treatment-related and immune-related 
grade 3/4 adverse events were more common in ipilimumab-
containing arms (concurrent 43% and 21%; phased 50% and 
17%; and control 30% and 9%). One treatment-related death 
due to hepatotoxicity was seen in the concurrent-treatment 
group. On the basis of these data, a randomized phase III 
trial of platinum-based chemotherapy (carboplatin or cispla-
tin and etoposide for four cycles) with or without phased ipi-
limumab in patients with extensive-stage SCLC is underway 
(NCT01450761). Tremelimumab is a fully human IgG2 anti-
body. A phase II trial failed to show an improvement in pFS 
when maintenance tremelimumab was compared with best 
supportive care (BSC) in patients with disease control (CR/
pR or SD) after four cycles of platinum-based chemotherapy 
(20.9% versus 14.3% patients progression free at 3 months).296 
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Nine (20.5%) of the tremelimumab patients experienced a 
grade 3/4 adverse effects the most common being diarrhea 
and colitis (9.1%). Studies with tremelimumab in combina-
tion with anti-pD-L1 therapy and gefitinib in patients with 
NSCLC are ongoing (NCT02000947; NCT02040064).
Anti-PD-1 Antibodies
Nivolumab (BMS-936558), a human monoclonal IgG4 
antibody, was the first anti-pD-1 antibody to demonstrate 
activity in NSCLC patients. pD-1 is an inhibitory T-cell recep-
tor that is engaged by it ligands pD-L1 (or B7-H1) and pD-L2 
(or B7-DC) predominantly within the tumor microenviron-
ment.297,298 promising activity was seen in a dose-escalation 
trial that included 129 NSCLC patients treated with nivolumab 
1, 3 or 10 mg/kg IV every 2 weeks in an 8-week cycle.299 An 
RR of 17.1% was noted in the NSCLC population with no sig-
nificant difference between squamous (16.7%) and nonsqua-
mous (17.6%) patients. Drug-related adverse events were seen 
in 53% of patients, 6% of which were grade 3/4 including gas-
trointestinal, pulmonary (pneumonitis), hepatitis, and infusion 
reactions.300 On subset analysis, no significant difference was 
seen in patients who were EGFR mutation positive or wild type 
or KRAS positive or wild type.301 There was a difference in RR 
between different dose levels; 3% for the 1 mg/kg cohort com-
pared with 24.3% and 20.3% for the 3 and 10 mg/kg cohort, 
respectively. On the basis of these data, the 3 mg/kg dose 
was selected for further study, including a single-arm phase 
II trial of nivolumab in squamous cell lung cancer patients 
(NCT01721759) and two randomized phase III trials compar-
ing nivolumab with second-line chemotherapy (docetaxel) in 
squamous and nonsquamous NSCLC patients (NCT01673867; 
NCT01642004). All three trials have completed accrual and 
results are anticipated. In patients enrolled in the phase I trial 
with tumor samples available for assessment, pD-L1 expres-
sion by IHC was associated with a response to therapy, whereas 
no responses were observed in patients with tumors that were 
pD-L1 negative.299 A phase III trial is ongoing comparing first-
line nivolumab to investigator-choice chemotherapy in patients 
with pD-L1–positive tumors (NCT02041533). promising 
results were seen in melanoma patients when nivolumab was 
combined with ipilimumab,300 and a phase I trial is currently 
evaluating nivolumab alone or in combination with ipilim-
umab in select tumor types including SCLC (NCT01928394). 
In addition, a phase I trial is ongoing evaluating nivolumab 
in combination with first-line platinum-based chemotherapy 
in NSCLC patients (NCT01454102). Initial data presented at 
ASCO in 2013 indicated a fairly high rate of grade 3/4 AEs 
(49%) for combination of nivolumab and chemotherapy.302
MK3475 is a humanized IgG4 anti-pD1 antibody that is 
also being evaluated in NSCLC patients. preliminary results 
from a phase I trial with MK-3475 10 mg/kg administered 
every 2 or 3 weeks reported a 24% response in the first 38 
evaluable patients using immune-related response criteria and 
a 21% RR using conventional RECIST response criteria.303 
This response was higher in patients with tumors that were 
positive for expression of pD-L1 (67% versus 4%). Median 
pFS had not been reached at the time of initial data cut off. 
Treatment-related adverse events, the majority of which were 
grade 1/2 were noted in 53% of patients including fatigue 
(16%), rash (16%), and pruritus (16%). Grade 3 pulmonary 
edema was reported in one patient and two patients experi-
enced grade 2 pneumonitis. Ongoing trials are comparing two 
different schedules of MK-3475 with standard chemotherapy 
(docetaxel) as second-line therapy in patients with tumors 
that are positive for pD-L1 expression (NCT01905657). In 
addition, MK-3475 is being combined with standard che-
motherapy and immunotherapy in an ongoing phase I trial 
(NCT02039674; NCT01840579).
Anti-PD-L1 Antibodies
BMS-936559, a fully human IgG4 molecule, was the 
first anti-pD-L1 antibody to demonstrate activity in NSCLC 
patients. An RR of 10% was observed in 49 patients enrolled 
in a phase I trial evaluating multiple different dose levels with 
no significant difference between squamous and nonsquamous 
NSCLC patients.304 Despite initial promising results, this agent 
is not being further explored in lung cancer patients at this time.
MpDL3280A is a human IgG1 monoclonal antibody to 
pD-L1. A phase I trial that included 85 NSCLC treated with 
MpDL3280A reported an RR of 23%.305 preliminary data 
reported that the RR was higher in tumors that were IHC3 
positive (83%), defined as 10% of tumors staining positive for 
expression of pD-L1 and in former and current smokers (11 
of 43) compared with never smokers (1 of 10).306 Treatment-
related adverse events occurred in 66% of patients, of which 
11% were grade 3/4 including fatigue, nausea, dyspnea, and 
emesis. Trials of MpDL3280A are ongoing in patients with 
tumors that are positive for expression of pD-L1, are ongo-
ing including a single-arm phase II trial of MpDL3280A 
(NCT01846416; NCT02031458), and a randomized phase III 
trial comparing MpDL3280A with standard chemotherapy 
(docetaxel) (NCT02008227). In addition, an upcoming phase 
I trial is combining MpDL3280A with or erlotinib in NSCLC 
patients (NCT02013219).
MEDI-4736 is a fully human antibody specific for 
pD-L1. Binding of MEDI-4736 relieves B7-H1–mediated 
suppression of T-cell activation in vitro. An ongoing phase I 
dose-escalation study including patients with NSCLC is eval-
uating different dose levels of MEDI-4736 including 0.1, 0.3, 
and 1 mg/kg every 2 or 3 weeks. Data reported on the first 11 
patients enrolled indicated toxicities similar to other agents 
in this class and responses observed in NSCLC patients.307 A 
phase Ib trial is evaluating MEDI-4736 in combination with 
tremelimumab in NSCLC patients (NCT02000947).
LUNG CANCER VACCINES
Cancer vaccines are based on immune system stimula-
tion through the use of tumor cell antigens. Once the immune 
system is activated, it may trigger a response to cells harbor-
ing these antigens, potentially leading to elimination of the 
malignancy.308 The two broad types of vaccines being evalu-
ated in patients with NSCLC are the tumor cell–based and 
the antigen-based vaccines. Because the antigens are usually 
poorly immunogenic by themselves, they are combined with 
potent adjuvants that stimulate the immune response to the 
vaccine without intrinsic antigenic effect.309
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Tumor cell vaccines
Belagenpumatucel-L
Belagenpumatucel-L is an allogeneic tumor cell vac-
cine made of four irradiated NSCLC cell lines (H460, 
H520, SKLU1, and RH2) modified with transformed growth 
factor-β2 antisense plasmid.310 Antisense gene inhibition with 
decreased cellular expression of transformed growth factor-β2 
increases the immunogenicity of the vaccine. In a random-
ized phase II trial, 75 patients with NSCLC stages II to IV 
were randomized to one of three doses (1.25, 2.5, or 5.0 × 107 
cells per injection) of the vaccine administered once every 1 
or 2 months for a maximum of 16 injections. The treatment 
was well tolerated and the two high-dose cohorts had a sig-
nificant improvement in OS compared with low dose. In the 
phase III phase III Lucanix™ Vaccine Therapy in Advanced 
Non-small Cell Lung Cancer (NSCLC) Following Front-line 
Chemotherapy (STOp) trial, 532 patients with NSCLC stage 
IIIA to IV were randomized to belagenpumatucel or placebo 
after frontline therapy.311 The study did not meet the primary 
end point with a median OS of 20.3 and 17.3 months in the 
vaccine and placebo arms, respectively (HR, 0.94; p = 0.59).
Among the 490 patients with stage IIIB or IV who 
were randomized within 12 weeks from completion of front-
line therapy, there was a 7.4-month improvement in OS for 
the vaccine arm, which did not reach statistical significance 
(20.7 versus 13.4 months; HR, 0.75; p = 0.083). In the subset 
of 99 patients with stage IIIB or IV non-adenocarcinoma, the 
median OS was significantly higher for the vaccine arm (19.9 
versus 12.3 months; HR, 0.55; p = 0.036). Therefore, although 
the study did not meet the end point, the authors suggested 
that selected subset analyses support the continued develop-
ment of belagenpumatucel-L in NSCLC.
Tergenpumatucel-L
Tergenpumatucel-L consists of three allogeneic lung 
tumor cell lines (derived from adenocarcinoma, squamous 
cell carcinoma, and large cell carcinoma) that were engi-
neered to express the α-galactosyltransferase enzyme, which 
is one of the major causes of hyperacute rejection induced 
with porcine xenografts transplanted into baboons.312 In a 
phase II trial, 28 patients with advanced NSCLC received ter-
genpumatucel-L 300 million cells per injection every 2 weeks 
for eight doses.313 The treatment was well tolerated without 
serious adverse events. Eight patients (29%) achieved SD for 
4 or more months, with five of 16 (31%) responding to subse-
quent therapy. The median and 1-year OS were 11.3 months 
and 46%, respectively. An ongoing phase III study is compar-




The melanoma-associated antigen-A3 (MAGE-A3) 
is an antigen with expression limited to nonmalignant cells, 
except for placental trophoblasts and testicular germ cells. 
MAGE-A3 is expressed in approximately 35% of patients 
with NSCLC. MAGE-A3 vaccine is composed of the protein 
plus the adjuvant AS15. In a phase II trial, patients with com-
pletely resected MAGE-A3–positive stage IB or II NSCLC 
were randomized to the vaccine (90 patients) administered in 
13 doses over 27 months or placebo (60 patients).314 Although 
the treatment was well tolerated, there were no statistically 
significant differences in disease-free interval, DFS, or OS. 
Nevertheless, the trend favoring the vaccine arm for dis-
ease-free interval (HR, 0.75), DFS (HR, 0.76), and OS (HR, 
0.81) led to the large phase III trial MAGE-A3 as Adjuvant 
non-small cell lunG cancer ImmunoTherapy (MAGRIT), 
where patients with resected stage IB to IIIA NSCLC and 
MAGE-A3–positive tumors were randomized to placebo or 
vaccine after adjuvant chemotherapy. The press release from 
GlaxoSmithKline on March 30, 2014, indicated that the trial 
enrolled 2312 patients worldwide and did not meet the pri-
mary end point of extending DFS.
Mucin-1
Liposomal BLp-25 (tecemotide) is a peptide-based vac-
cine consisting of a synthetic mucin 1 (MUC-1) lipopeptide 
combined with the adjuvant monophosphoryl lipid A and three 
lipids forming a liposomal product. In a phase II study, 171 
patients with stage IIIB or IV NSCLC and no progressive dis-
ease (pD) after first-line therapy were randomized to BSC or 
vaccine with 1000 µg weekly for 8 weeks followed by adminis-
trations every 6 weeks until tumor progression.315 The vaccine 
was preceded by one dose of cyclophosphamide 300 mg/m2. 
This low-dose cyclophosphamide, administered 3 days before 
the immunotherapy, does not have significant antitumor activ-
ity in NSCLC and was used to increase the immune response. 
The study did not meet the primary end point with median OS 
increasing from 13 months in the BSC arm to 17.4 months in 
the vaccine group (p = 0.66). The greatest benefit for the vac-
cine was in the subset analysis of patients with locoregional 
stage IIIB disease, where the post hoc analysis showed that both 
median (not reached versus 13.3 months) and 2-year OS (60% 
versus 36.7%) favored the experimental arm. The Stimulating 
Targeted Antigen Responses To NSCLC trial was a large inter-
national, randomized, double-blind, clinical study that random-
ized patients with stage III NSCLC who did not have pD after 
chemoradiotherapy, compared with tecemotide or placebo.316 
After the primary treatment, 829 and 410 patients were ran-
domized to tecemotide and placebo, respectively. The study 
did not meet the primary end point of improving OS, with the 
median OS increasing from 22.3 months in the placebo to 25.6 
months in the tecemotide arm (HR, 0.88; p = 0.12). Subset 
analysis of patients receiving concurrent chemoradiotherapy 
showed an improved median OS for the 538 patients receiv-
ing tecemotide compared with the 268 patients randomized 
to placebo (30.8 versus 20.6 months; HR, 0.78; p = 0.016). 
A randomized phase III trial comparing tecemotide with pla-
cebo in patients with stage III NSCLC treated with concurrent 
chemoradiotherapy (Stimulating Targeted Antigen Responses 
To NSCLC trial 2) started in March 2014. A phase III trial 
(Tecemotide liposome vaccine trial In Asian NSCLC patients: 
Stimulating Immune REsponse [INSpIRE] with an almost 
identical design is being conducted in Asia.
TG4010 is a vaccine composed of the modified vaccinia 
virus Ankara containing the sequence for the MUC-1 antigen 
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and interleukin-2. In a phase II trial, two schedules of cisplatin 
plus vinorelbine and TG4010 were evaluated, including concur-
rent therapy upfront and TG4010 followed by the combination 
at progression.317 Because only two of the initial 21 patients in 
the sequential arm achieved SD for more than 6 months, this 
strategy did not meet criteria by the two-stage Simon design for 
further evaluation. In the concurrent arm, 13 of 37 evaluable 
patients (35%) achieved pR, with a median OS of 12.7 months 
and 1-year OS of 53%. In the phase IIB trial, 148 patients with 
stage IIIB with malignant pleural effusion or stage IV NSCLC 
were randomized to cisplatin plus gemcitabine alone or in com-
bination with TG4010.318 The primary end point of the study of 
pFS at 6 months was met, with a significant prolongation in the 
vaccine arm compared with chemotherapy alone (43.2% versus 
30%, p = 0.01). The experimental arm was also associated with 
increased in RR (41.9% versus 28.4%) and median OS (23.3 
versus 12.5 months). A confirmatory phase IIB/III trial (TIME) 
started in January 2012 and allows a chemotherapy choice 
among multiple platinum-based doublets.
OPTIMAL TRIAL DESIGN IN THE  
ERA OF GENOMICS
Advancements in NGS technologies have resulted in a 
dramatic shift in the clinical trials paradigm such that cancer, 
once defined by many pathologically defined tumor types, is 
considered to be a disease of the genome consisting of copious 
small molecular subsets. This has motivated tailoring therapy 
with molecularly targeted agents and resulted in re-examina-
tion of clinical trials conduct in light of the rarity of certain 
genetic aberrations, the desire to bring new drugs to market 
more quickly, and financial resources. Here, we outline some 
current issues with the design of clinical trials with respect to 
the bench-to-bedside approach of drug development.
Early Drug Development
National and international efforts such as TCGA and the 
International Cancer Genomics Consortium have catalogued 
genetic aberrations of dozens of tumor types across thousands 
of candidate genes, resulting in massive public data sets and 
innumerable hypotheses for new therapeutic targets.319–321 
When paralleled by the advancement and reduction in costs 
for the associated technologies and the scientific successes of 
targeted agents such as imatinib and crizotinib in phase I tri-
als, the number of phase I studies enrolling patients by molec-
ular abnormality is increasing, as is the size of their expansion 
cohorts, even though there is little statistical design literature 
to support this approach.12,321–327 The expansion cohort has 
gradually morphed from an opportunity to learn more about 
the safety of a novel agent to one in which efficacy data are 
becoming of increasing importance despite a general lacking 
of any expectation of statistical design for them. Often, the 
total sample size of the expansion cohort may exceed the sam-
ple size anticipated in the phase II setting, where one would 
otherwise formally test a prespecified hypothesis with clearly 
stated type I and type II error rates. The problem with not 
incorporating a trial design in this setting is that any expan-
sion cohort may be deemed a success from being subjected 
to many subset analyses by histopathology, genetic mutation, 
and/or outcomes. Statistically, this type of “sampling to a fore-
gone conclusion” will result in false-positive findings; as this 
practice becomes more common and omics-based tests are 
more likely to impact this setting, discussions about whether 
these cohorts truly serve the “phase I intent” should be revis-
ited. Consideration of unambiguous rules for stopping and 
study success should also be given to expansion cohorts in 
light of the historically low RR on phase I trials and the goal 
of minimizing exposure to ineffective or toxic drugs.
Phase II and Phase III Studies
To prevent premature advancement of genomic tests 
for guiding treatment decisions, one of the significant recent 
advancements in the design of oncology clinical trials has 
been the development of a 30-point checklist to determine 
the readiness of omics-based tests for guiding patient care in 
clinical trials by the National Cancer Institute.328 The criteria 
apply to any trial in which the investigational use of a labora-
tory test will impact therapy and cover a wide range of topics 
from establishing standards for sample collection to acquiring 
strong evidence in support of the test to feasibility, ethics, and 
legal issues. It is important to note that several of the checklist 
criteria also apply to studies of single biomarkers, or panels of 
biomarkers, measured by conventional methods as opposed to 
high-throughput methods.
Assuming that the criteria from the checklist described 
above are met, the next step is determining the optimal trial 
design for evaluation of a therapy in the phase II or phase III 
setting. This choice of design may vary depending on the situ-
ation, but the fundamental statistical principles for power and 
type I error rate considerations still apply for each phase of 
development. An enrichment design is appropriate when there 
is strong evidence that a molecularly targeted agent improves 
outcomes among patients diagnosed with a cancer harboring 
a particular biomarker; this type of trial enrolls only those 
patients who test positive for the marker of interest, and in this 
setting, the biomarker is referred to as a selection marker.329,330 
The efficiency of the enrichment design depends on propor-
tion of patients with the marker of interest and the level of 
efficacy among patients without the marker of interest. The 
results obtained from these types of trials may not necessar-
ily be generalizable to populations of patients with different 
tumor types characterized by the same marker.
If there is evidence that a therapy may benefit the 
marker-positive and marker-negative patients, one can use 
marker status as a stratification factor in a randomized trial to 
ensure that the treatment assignment is equal within marker 
subsets. If the goal is to demonstrate that a new agent has a 
dramatically different effect on outcome in one marker group 
than in another, then it would also be appropriate to power and 
test for a marker by treatment interaction—this is statistically 
the only way in which one may declare a candidate marker 
as “predictive.” It is not appropriate to declare a marker as 
predictive simply by observing differential relative outcomes 
between the two groups of patients. If this latter situation is 
likely the case, then another design option may be powering 
the study for an overall treatment effect as well as for tests of 
efficacy within each of the marker subgroups. With this type 
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of design, treatment assignment depends on marker status, 
so it is critical that test results be returned within a reason-
able timeframe so that randomization may take place, and the 
planned marker subgroup analyses should be specified in the 
protocol a priori. In the event that the marker analysis must be 
done retrospectively, for example, due to feasibility issues or 
issues with assay development, one may still be able to obtain 
meaningful results in favor of prediction.331,332
At this time, randomized designs remain the standard 
procedure and are being implemented to validate the clini-
cal utility of a single biomarker, but implementation of these 
studies can be challenging for two reasons: first, the rarity of 
some tumors can dramatically hinder study accrual and make 
for longer study durations, and second, at this time, we often 
proceed with designing a study under the assumption that the 
molecularly targeted population is characterized by the same 
response to standard of care as the entire population when 
establishing a null hypothesis for the control group. The latter 
may not actually be the case, and in the event that a genetic 
aberration confers better outcomes than a design had planned, a 
randomized study may be underpowered to detect the improve-
ment in outcome for which it was designed. To counter these 
concerns, nonrandomized designs may appropriate in some 
settings but come with the caveat that response or duration of 
response are really the only reliable efficacy end points and 
are generally more common in earlier phases of drug develop-
ment, with confirmatory experience to follow after registration 
since drugs often look promising in preliminary studies and do 
not always translate to improvements in clinical outcomes.333
predictive oncology has also spurred the research com-
munity to re-evaluate the target effect sizes incorporated in 
statistical designs. The bar is much higher now. The dramatic 
improvement in efficacy with drugs such as crizotinib and erlo-
tinib in targeted populations has demonstrated that large effect 
sizes are possible, and that the relatively resource-intense 
approach of designing studies to detect small differences that 
may not be clinically meaningful does not parallel the goals of 
rapid discovery and efficiency of the cancer genome era.
Platform Studies
The era of genomics has also motivated the oncology 
community to re-examine the way that phase II and III stud-
ies are conducted such that “platform designs” are quickly 
becoming the new standard. These trials enroll thousands of 
patients to a single protocol for genomic screening and treat-
ment assignment to a substudy based on the genetic character-
istics of their disease. Examples of such efforts currently under 
development are the The Adjuvant Lung Cancer Enrichment 
Marker Identification and Sequencing Trials (ALCHEMIST), 
Southwest Oncology Group 1400 (LUNG-MAp), Molecular 
profiling based Assignment of Cancer Therapeutics (M-pACT), 
and Molecular Analysis for Therapy Choice (MATCH) trials. 
Although each of these differs in terms of the statistical designs 
and end points used by each of the trials encapsulated by the 
overarching platform, it is believed that these now serve as the 
new model for trial conduct and will result in more rapid drug 
discovery and more definitive trials. These studies also have the 
advantage of profiling all the tumors in a standard manner in a 
single protocol, but come with some hurdles as well, such as 
securing drug supply across multiple sponsors and some uncer-
tainty about the ability to accrue a sufficient number of patients 
with each aberration of interest.
Summary
Some research areas that are likely to further influence 
the design and conduct of clinical trials in the era of genom-
ics include studies of intratumoral heterogeneity, epigenetics, 
mechanisms of resistance, and clonal evolution. presumably 
more “trials of n = 1” will surface, but it is important to recall 
that “the pleural of anecdote is not data” and that, while play-
ing a role in hypothesis generation, these types of experi-
ences are not comparable with prospectively designed studies. 
Moving forward, many of the fundamental principles of trial 
design, such as adequately powering a study and controlling 
the false-positive rate, will remain even as our design change. 
With national and international collaborations that carefully 
consider all aspects of the research process, transformative 
clinical trials will continue to impact patient care.
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